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SUMMARY
Serum thyrotrophin (TSH) levels have been measured by radioimmunoassay
in a large series of new patients referred to the Endocrine Clinic,
Royal Infirmary, Edinburgh with suspected thyroid disease. The
normal range for the assay has been established at undetectable -
5.7 mU/1. Raised levels of serum TSH have been found in patients
with untreated primary hypothyroidism and in patients with impaired
reserve of thyroid function, and it has been shown that a single
estimation of serum TSH gives similar information about thyroid
reserve as the time-consuming TSH stimulation test. It has not been
possible, on the basis of a single estimation of serum TSH, to
differentiate the euthyroid patient from the hyperthyroid patient.
However, a lack of response of the serum TSH level to thyrotrophin-
releasing hormone (TRH) intravenously has been shown to be compatible
with a diagnosis of thyrotoxicosis. The measurement of serum TSH
level before and at twenty minutes after TRH showed good correlation
with the results of the triiodothyronine suppression test, and the
TRH test should therefore replace the suppression test in the
investigation of patients with suspected thyrotoxicosis in whom the
results of routine thyroid function tests are equivocal. Serum TSH
levels have been found to be significantly lower in patients with
simple non-toxic nodular goitre than in euthyroid non-goitrous
patients or in patients with simple non-toxic diffuse goitre, and
may be a reflection of thyroid autonomy in nodular goitre.
Thyroid function has been assessed in patients treated with iodine-131
for thyrotoxicosis. Due to a suppression of the brain-thyroid axis in
patients previously exposed to high circulating levels of thyroid
hormones, the total serum thyroxine level was a better index of
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impending hypothyroidism than the serum TSH level in the early weeks
after radioiodine treatment. Raised levels of serum TSH have been
found in over 50% of patients euthyroid six to eighteen years after
iodine-131 therapy for thyrotoxicosis. The patients with a raised
serum TSH level were shown to be at risk of developing hypothyroidism
at- a rate of 2-5% per annum over a period of three years of study,
whereas no patient with a normal serum TSH level developed hypo¬
thyroidism over the same study period. It is suggested that the long-
term follow-up policy for the ever-increasing number of patients who
have been treated with radioiodine for thyrotoxicosis could be
rationalised on the basis of the serum TSH level measured at one year
after therapy.
The efficacy of treating patients with thyrotoxicosis by subtotal
thyroidectomy under cover of propranolol has also been demonstrated.
The time for recovery of the suppressed brain-thyroid axis in such
patients has been shown to be between four and eight weeks. The
phenomenon of temporary clinical hypothyroidism in the early weeks
after subtotal thyroidectomy has been described in terms of total
serum triiodothyronine and thyroxine and TSH levels and attention has
been drawn to the possibility that the timing of postoperative review
may be related in part to the postoperative incidence of hypothyroidism.
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CHAPTER 1 Serum TSH levels in thyroid disease
Since the description of a sensitive and specific radioimmunoassay of
human serum thyrotrophin (TSH) by Odell et al. (1965) and Utiger (1965)
the estimation of circulating TSH in the investigation of patients
with thyroid disease has proved a valuable additional test of thyroid
function (Hall et al. 1971; Hershman and Pittman, 1971; Mayberry et
al., 1971; Patel et al., 1971). The development of a double-antibody
radioimmunoassay for serum TSH in Edinburgh has afforded the
opportunity of measuring serum TSH levels in a large series of
patients referred to a thyroid clinic. The present report is
concerned-with the definition of a normal range for serum TSH and with
the evaluation of serum TSH levels in the diagnosis of patients with
suspected thyroid disorders.
PATIENTS AND METHODS
A total of five hundred and eighty-one new patients were studied who
had been referred to the Endocrine Clinic, Royal Infirmary, Edinburgh
for the investigation of suspected thyroid disease. In each case the
thyroid status was determined clinically and on the basis of the
following tests of thyroid function: total serum thyroxine (T^) by
competitive protein-binding analysis (Seth, 1973) or radioimmunoassay
(Seth et al., 1975), effective thyroxine ratio (ETR) (Thorson et al.,
1972; Toft et al., 1973a), circulating thyroid autoantibodies
(Doniach and Roitt, 1975) and the 4 hour uptake of iodine-132 by the
thyroid gland supplemented when necessary by TSH stimulation or
triiodothyronine (T^) suppression. In addition thyroid biopsy was
performed in some of the patients with suspected Hashimoto's thyroiditis.
No evidence of thyroid disease could be found' in two hundred and twenty
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of the patients (185 females, 35 males) with a mean age of thirty-
eight years, of whom twenty-nine patients were taking an oestrogen
containing oral contraceptive agent at the time of presentation.
Circulating thyroid autoantibodies were present in thirty-five of the
patients (16%) in this group.
Three patients, all female, were considered to have exophthalmic
Graves' disease, on the basis of unilateral exophthalmos associated
with thyroid autoantibodies and an abnormal suppression test
result.
A diagnosis of Hashimoto's thyroiditis was made in sixteen patients
(15 female, 1 male) with a mean age of forty-three years. In each
case a firm, symmetrical enlargement of the thyroid gland was
present and was associated with clinical and biochemical evidence of
hypothyroidism in five patients, and in three of these five patients
thyroid autoantibodies were present in the serum. The remaining
eleven patients with Hashimoto's thyroiditis were euthyroid,
although the TSH stimulation test was abnormal in eight: in six of
the euthyroid patients, thyroid autoantibodies were either
undetectable or present in the serum in weak titre and the
diagnosis of Hashimoto's thyroiditis was confirmed by histological
examination of the gland; in the other five patients the
combination of a firm symmetrical goitre and a tanned red cell
haemagglutination titre of 1:2500 or more and/or a complement
fixation titre of 5:1:32 was considered adequate for diagnostic
purposes.
Thirty-three patients (31 females, 2 males) with a mean age of
fifty-three years were found to have primary (non-goitrous)
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hypothyroidism. Three of the patients had previously been treated
with iodine-131, and two by subtotal thyroidectomy for thyrotoxicosis.
In all cases a low total serum T, level and a low ETR was associated
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with a lack of response of the 4 hour iodine-132 uptake by the thyroid
gland to exogenous TSH stimulation. Thyroid autoantibodies were
present in 75% of the patients.
Secondary hypothyroidism as a result of anterior pituitary or
hypothalamic dysfunction was present in ten patients (4 females, 6 males)
with a mean age of forty-two years. In each case low circulating
levels of thyroid hormone were associated with a normal TSH
stimulation test result. In three of the patients the
hypothyroidism was associated with idiopathic panhypopituitarism, in
two patients it was secondary to a hypothalamic lesion and in four
patients it was the result of hypophysectomy for a pituitary
adenoma. The remaining patient was considered to have a
combination of partial thyroid and partial pituitary failure.
A simple non-toxic goitre was present in one hundred and fifteen
patients and was classified as diffuse or nodular on clinical grounds
alone in the majority. In fifty-two patients (50 females, 2 males)
with a mean age of twenty-nine years the thyroid gland was diffusely
enlarged. A nodular goitre was present in sixty-three patients (60
females, 3 males) with a mean age of forty-seven years. A solitary
nodule was present in eight of these patients and in six a partial
thyroidectomy was carried out and the histology shown to be that of
a benign thyroid adenoma. Partial thyroidectomy was also performed
in fourteen of the patients with multinodular goitre and in each case
the histological appearances confirmed the clinical diagnosis and did
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not indicate Hashimoto's thyroiditis. Thyroid autoantibodies were
present in five patients with diffuse goitre and in fifteen patients
with nodular goitre. The titres in the complement fixation test and
in the tanned cell haemagglutination test in no case exceeded 1 in 8
and 1 in 250 respectively which are below the levels suggestive of
Hashimoto's thyroiditis and which commonly occur in control
populations.
Thyrotoxicosis was diagnosed in one hundred and eighty-four patients
f
(155 females, 29 males) with a mean age of forty-two years, and
thyroid autoantibodies were present in the serum of 65% of the
patients.
The radioimmunoassay of serum TSH was carried out using a
modification of the double antibody method of Odell et al. (1967a).
Purified human TSH (Preparation DE-32-3) for iodination was
provided by Dr. A. Stockell Hartree, Cambridge University, and the
Medical Research Council human TSH standard A was used as a standard.
Guinea-pig anti-TSH serum was raised by the MRC Radioimmunoassay Team,
Edinburgh, and rabbit antiserum to guinea-pig8 -globulin was used as
the precipitating antibody. In ten consecutive assays the mean and
range of binding to antibody of the 50 ng/1 iodine-125-TSH tracer
was 47.3 (41.9-54.5)%, while 25%, 50% and 75% inhibition of this
binding was given by 0.55 (0.49-0.60), 1.30 (1.10-1.35) and 3.70
(2.50-3.80) mU/1 incubate respectively. Serum was assayed at 1:4
or greater dilution as appropriate. No attempt was made to equalise
the serum content of the incubates by incorporating human TSH-free
serum in the standards because the small intrusion of non-specific
interference as represented by the response of different samples of
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non-primate serum was inconstant. Responses which were not greater
than 10% binding below the '0' standard were recorded at less than
the appropriate value. The mean value for this threshold was 1.84
(range 1.60-2.12) mU/1 serum in the ten assays described above.
RESULTS
The levels of serum TSH recorded in the five hundred and eighty-one
patients with suspected thyroid disease are shown in Fig. 1.1 in
relation'to the final diagnosis.
Normal Range
The normal range for the TSH assay was calculated from the serum
TSH levels of the one hundred and ninety-one patients (156 females,
35 males) in whom no evidence of thyroid disease could be found and
who were not receiving an oestrogen containing oral contraceptive
agent. The results conformed to a log normal distribution and the
mean serum TSH level and the 95% tolerance limits calculated on this
basis were 2.7 and<1.8-5.7 mU/1 respectively. The normal range
for serum TSH was therefore considered to be <1.8-5.7 mu/1.
The euthyroid patients represented in Fig. 1.1 include the twenty-nine
females taking oestrogen containing oral contraceptives, and the three
females with exophthalmic Graves' disease. Forty (18%) of the total
two hundred and twenty-three euthyroid patients had a serum TSH
level of <1.8 mU/1. It is of interest that thyroid autoantibodies
were detected in the serum of three of the four euthyroid patients
with the highest serum TSH levels. Serum TSH levels were
uninfluenced by age, sex or oestrogens.
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Hashimoto's thyroiditis
The serum TSH levels were elevated in all but three of the patients
with Hashimoto's thyroiditis. The five patients who were clinically
hypothyroid had serum TSH levels ranging from 25.2-93.0 mU/1, and
the eight euthyroid patients with raised serum TSH levels had
values of 6.2-19.8 mU/1.
]i££roary_hypothyroidi sm
In all patients with primary hypothyroidism the serum TSH levels
were markedly elevated, ranging from 21.2- 512.O mU/1. There was
no apparent relationship between serum TSH concentration and age,
duration of symptoms or titre of thyroid autoantibodies.
Secondary hypothyroidism
In three patients in this category the serum TSH level was undetectable
and in four patients lay between 1.8 and 5.7 mU/1. In the two
patients with hypothalamic lesions, the serum TSH level was
minimally raised at 5.9 and 6.4 mU/1. In the remaining patient in
whom a diagnosis of hypothyroidism secondary to a combination of partial
thyroid failure and partial pituitary failure was made, the serum TSH
level was 30.0 mU/1. In view of the unusual aetiology of
hypothyroidism in this latter patient, the case will now be
described in more detail: the patient was a 58 year-old female
schoolteacher who presented with the features of myxoedema. There
was no goitre. The total serum T^ was <25 nmol/1, serum TSH 30.O mU/1
and antibodies were detected to thyroglobulin in a titre of 1:2500 by
the tanned cell haemagglutination method. Antibodies against thyroid
cytoplasm were not detected. The 4 hour iodine-132 uptake by the
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thyroid gland increased normally from 13-26% in response to
exogenous bovine TSH, 10 i.u. intramuscularly daily for three
consecutive days, suggesting a diagnosis of secondary hypothyroidism.
Tomography of the pituitary fossa was normal and the visual fields
were intact. Urinary luteinising hormone (LH) measured by
haemagglutination inhibition was low for a post-menopausal female
at 23.3 IU/24 hours (normal >36 IU/24 hours). A standard insulin
tolerance test was performed, using O.l units soluble insulin/Kg -
body weight. The plasma glucose fell to <1.0 mmol/1, but the
serum growth hormone (GH) level measured by radioimmunoassay
(HGH-125 Imusay, Abbott Laboratories) was undetectable throughout the
test. The plasma 11-hydroxycorticosteroids (11-OHCS) (Mattingly, 1962)
and the plasma prolactin measured by radioimmunoassay (Cole and Boyns,
1973) increased normally from 480 to 1250 nmol/1 and from 0.19 to
0.59 U/l respectively. The elevated basal serum TSH level of 30.0
mU/1 indicative of primary thyroid failure was unchanged however, at
twenty and sixty minutes after the rapid intravenous injection of 200yg
thyrotrophin-releasing hormone (TRH), suggesting that the pituitary
thyrotrophs were already secreting TSH to their maximum capacity.
When the patient had been taking 1-thyroxine 0.15 mg daily for five
months the brain-thyroid axis was reinvestigated. She was clinically
euthyroid, with a total serum T^ of 100 nmol/1 and a serum TSH level
of <1.8 mU/1 which remained undetectable following 200 yg TRH
intravenously. Urinary LH remained low at 26.2 IU/24 hours. Serum
GH increased on this occasion to 8.0 mg/1 during insulin-induced
hypoglycaemia, the plasma glucose falling to <1.0 mmol/1. Plasma
11-OHCS and prolactin levels rose normally during the test. The
patient has been followed up for three years and remains well. There
is no clinical or radiological evidence of pituitary tumour. The
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degree of impaired function of either thyroid or pituitary gland
alone would not have caused the clinical presentation, and the only
satisfactory explanation of the results of the various
investigations is that the myxoedema was a consequence of a
combination of partial failure of the thyroid gland and the
anterior pituitary gland.
Simple non-toxic goitre
The serum TSH levels in the patients with diffuse enlargement and in
the patients with nodular enlargement of the thyroid gland are
shown in Fig. 1.2. The serum TSH levels in the one hundred and
ninety-one patients with no evidence of thyroid disease are
included for comparison. The results conformed to a log normal
distribution and the mean levels and the 95% tolerance limits
calculated on this basis are shown in Table 1.1. Although the mean
serum TSH levels of the two groups of patients with simple non-toxic
goitre lay within the normal range, it was apparent that a different
distribution of serum TSH levels existed between the patients with
nodular goitre and those with diffuse goitre or those euthyroid
patients without goitre in that a greater proportion of patients with
nodular enlargement of the thyroid gland had undetectable levels of
TSH in the serum of <1.8 mU/1 (57%) when compared with the patients
with diffuse thyroid enlargement (29%) or with those without goitre
(18%). Due to the uncertain nature of the distribution of the serum
TSH results below 1.8 mU/1 the Mann-Whitney U test was employed as a
non-parametric test of significance (Siegel, 1956) to determine any
difference in serum TSH levels in the three groups of patients. Using
this test, the serum TSH levels in the patients with nodular goitre
were significantly lower than those recorded in either the patients with
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diffuse thyroid enlargement or the non-goitrous euthyroid patients
(P <0.01 and P <0.0001), and this difference was maintained when the
patients with evidence of circulating thyroid autoantibodies were
excluded (P <0.0001 and P <0.0001). The difference between the
groups could not be accounted for by age, as there was no apparent
relationship between serum TSH levels and age in the control group.
There was, however, no statistical difference in serum TSH levels
between patients with diffuse goitre and non-goitrous euthyroid
patients with or without evidence of circulating thyroid
autoantibodies (P>0.8 in each case).
It is of interest that seven of the patients with diffuse thyroid
enlargement had raised serum TSH levels which on the one hand may
represent the initial stimulus to goitre formation, but on the other
hand may be the result of undetected autoimmune thyroiditis or
dyshormonogenesis. In three of the five patients with nodular
goitre and elevated serum TSH levels, antibodies to thyroid
microsomes were detected by immunofluorescence, but the complement
fixation titre was less than 1:4 and thyroglobulin antibodies were
absent in each case.
Thyrotoxicosis
The serum TSH level was undetectable at <1.8 mU/1 in one hundred and
sixty-nine (92%) of the patients with thyrotoxicosis. The
remaining fifteen patients with thyrotoxicosis had serum TSH levels
of between 1.8 and 5.7 mu/l which is the upper limit of normal
established for the euthyroid patients with no evidence of thyroid
disease. No patient with thyrotoxicosis had a raised level of serum
TSH.
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DISCUSSION
All published reports of the radioimmunoassay of TSH have
established a normal range from serum TSH levels found in hospital
in-patients and healthy vounteers. Such a method is epidemiologically
unsatisfactory (Masi, 1965) and there are alternative approaches for
the determination of a normal range for serum TSH. One method is to
measure circulating TSH levels in a large scale community survey and
it is of interest that the upper limit of normal for serum TSH on
this basis in the Newcastle-upon-Tyne area is 5.0 mU/1 (Evered et al.,
1975), which is significantly higher than the upper limit of normal
of 2.8 mU/1 proposed by Hall et al.,(1971) utilising the same
radioimmunoassay system, but depending upon a small number of
hospital controls. The other approach is to calculate a normal
range or more precisely a clinic euthyroid range, from the levels of
serum TSH estimated in patients referred to a thyroid clinic with
suspected thyroid disease, but who are ultimately found to be
clinically and biochemically euthyroid with no evidence, past or
present, of thyroid disease. It is felt that such a group of
patients is well matched with the patients who are found to have
disordered thyroid function, since each group has been selected only
on the basis of suspected thyroid disease from the same population
and by means of the same hospital referral system. It is of
interest that the normal range so established of <1.8-5.7 mU/1 has an
upper limit of normal close to that reported from the population
survey in Newcastle of 5.0 mU/1. The lower limit of sensitivity of
the present assay of 1.8 mU/1 is higher than that reported in many
other assay systems, but can be mainly accounted for by the fact that
in the Edinburgh assay binding responses which are less than 10%
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below the 'O' standard of the standard curve are recorded as
undetectable levels of serum TSH.
The only comprehensive study of serum TSH levels in autoimmune
thyroiditis is that of Greenberg et al., (1970) who estimated
thyroid function in children with chronic lymphocytic thyroiditis
in whom there was histological confirmation of the diagnosis in each
case. Raised serum TSH levels were found in nineteen of the thirty-
two euthyroid patients. Serum TSH levels showed a good correlation
with the degree of follicular epithelial atrophy within the thyroid
gland. There is no similarly detailed study available in adult
patients with Hashimoto's thyroiditis. Mayberry et al., (1971)
reported elevated serum TSH levels in 38% of euthyroid patients
with Hashimoto's thyroiditis, but histological confirmation of the
diagnosis was available in only half of the patients and no attempt
was made to relate serum TSH levels to thyroid histology. Eight of
the eleven euthyroid patients with Hashimoto's thyroiditis in the
present series had raised serum TSH levels, but the number is too small
to permit informed comment. There is no doubt, however, that a
raised serum TSH level in a patient with a symmetrical goitre and
with circulating thyroid autoantibodies prevents the need for
histological confirmation of the diagnosis of autoimmune thyroiditis
since serum TSH levels in patients with simple goitre and carcinoma
are normal or low. Although patients with congenital dyshormonogenesis
may have high levels of serum TSH, antibody titres are rarely
significantly increased (Anderson et al., 1959). It remains to be
seen whether the natural history of Hashimoto's thyroiditis in a
patient with a normal serum TSH level and presumably mild disease will
differ from that of the patient with a raised serum TSH level and
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more extensive destruction of the thyroid gland.
The serum TSH level exceeded 20.0 mU/1 in all the patients with
primary hypothyroidism, a total of one hundred and nine patients if
the patients described in the TSH stimulation test and TSH 'short-
feedback" studies are included. There is therefore a range of TSH
in the serum from 5.7-20.0 mU/1 which is seen in patients who are
euthyroid but have some degree of impairment of thyroid reserve.
Prior to the development of overt hypothyroidism a patient must pass
through two stages of impaired reserve of thyroid function. In the
first stage there is a tendency for thyroid hormone levels to
deviate downwards from the optimum level and for pituitary TSH
secretion to increase, but while there is adequate thyroid reserve
the total serum T^ and T^ are returned to normal levels. Such
patients, who are asymptomatic, have been classified as having
subclinical or preclinical hypothyroidism (Evered and Hall, 1972;
Evered et al., 1973a). Some aspects of preclinical hypothyroidism
have been described in terms of circulating thyroid autoantibodies
(Bastenie et al., 1967a; Bastenie et al., 1967b; Vanhaelst et al.,
1967; Bastenie et al., 1971; Gordin et al., 1972; Gordin et al.,
1974) or in terms of raised serum cholesterol concentrations (Fowler
and Swale, 1967; Fowler et al., 1970). Although some patients
with preclinical hypothyroidism will have circulating thyroid auto¬
antibodies and/or a raised serum cholesterol level, neither of these
phenomena is specific, and the definition should be retained for
asymptomatic patients with a raised serum TSH level and normal
levels of circulating thyroid hormones. In the second stage of
impaired reserve of thyroid function, despite rising levels of serum
TSH, the concentrations of total serum T and T are not maintained
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and deviate downwards although still within the normal range. Many
of these patients are considered to have mild hypothyroidism on the
basis of non-specific symptoms and a subjective response to thyroxine
replacement therapy (Evered et al., 1973a). However, the greatest
incidence of patients with thyroid hormone levels in the lower part of
the.normal range and raised serum TSH levels occurs following treatment
of thyrotoxicosis with radioiodine or surgery. In several large
series (Tunbridge et al., 1974; Evered et al., 1975; Toft et al.,
1973c, 1974a, 1975 and Chapter 5) such patients have not been
considered to have mild hypothyroidism as they have not received
replacement therapy with thyroxine. It is evident that there is no
agreement about where the division lies between impaired thyroid
reserve and hypothyroidism and in Edinburgh it is felt that the
diagnosis of primary hypothyroidism requires a demonstration of a low
circulating level of total serum thyroxine which will be invariably
associated with serum TSH concentration of >20.0 mU/1. Patients
with total serum T^ levels in the lower range of normal associated
with raised serum TSH levels are considered to be euthyroid although
it is possible that long-term studies of this group of patients may
prove that the withholding of thyroxine replacement therapy is
detrimental.
On the basis of the current understanding of the brain-thyroid axis,
serum TSH levels should be undetectable in patients with hypothyroidism
secondary to pituitary or hypothalamic disease. However, the
spectrum of results for serum TSH recorded in patients with
secondary hypothyroidism in the present series, from undetectable
to slightly raised levels, is an agreement with the reports of other
/
investigators (Patel and Burger, 1973; McLaren et al., 1974). The
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finding of detectable levels of serum TSH within the normal range in
secondary hypothyroidism may be explained by the lack of sensitivity
of the assay. It is more difficult to account for the presence of
raised serum TSH levels in such patients unless there is associated
primary thyroid failure as suggested in the patient in the present
study in whom a serum TSH level of 30 mU/1 was detected which did
not rise further after TRH, and in whom the TSH stimulation test
result was normal and autoantibodies were present in high titre to
thyroid tissue. Patel and Burger (1973) reported almost 50% of a
series of -patients with secondary hypothyroidism to have slightly
raised serum TSH levels, although concomitant thyroid failure based
on the presence of circulating thyroid autoantibodies and a lack of
thyroidal response to exogenous TSH was present only in the minority.
However, the recent description of autoantibodies to prolactin
secreting cells of the human pituitary in patients with one or more
autoimmune endocrine diseases (Bottazzo et al., 1975) gives credence
to the possibility that pituitary and thyroid failure may coexist in
the same patient. It is also possible that biologically inactive
fragments or precursors of TSH which cross-react with the TSH anti¬
serum are released in some of the patients with secondary
hypothyroidism. Whereas the serum TSH level is of value in
determining whether a patient has primary or secondary hypothyroidism,
it was hoped that the serum TSH response to TRH would demonstrate
whether the site of functional impairment was of pituitary or
hypothalamic origin. An absent or subnormal serum TSH response to
TRH is found in patients with hypopituitarism (Anderson et al., 1971;
Haigler et al., 1971; Hall et al., 1972) and a serum TSH response to
TRH of normal magnitude but delayed time course occurs in patients
/
with hypothalamic disease (Costom et al., 1971; Hall et al., 1972).
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However, since absent, subnormal or delayed responses may occur
in patients who are euthyroid or hypothyroid with pituitary or
hypothalamic disease (Foley et al., 1972; Patel and Burger, 1973;
McLaren et al., 1974; Snyder et al., 1974), and since high basal
levels of serum TSH with exaggerated responses to TRH have been
reported in patients with pituitary tumours (Faglia et al., 1972;
Schalch et al., 1972; McLaren et al., 1974) the significance of the
patterns of serum TSH response to TRH is not always clear.
The cause- of sporadic non-toxic goitre is not known and from the
present study it is evident that a raised serum TSH level is not
required for the maintenance of thyroid enlargement, unlike the
situation in areas of severe iodine deficiency where serum TSH
levels are raised in association with goitre (Buttfield et al., 1966;
Pisarev et al., 1970; Wahner et al., 1971; Beckers and Cornette, 1971;
Delange et al., 1971; Ogihara et al, 1972; Kochupillai et al., 1973).
Although it is possible that the thyroid gland of patients with sporadic
goitre is more sensitive to the goitrogenic action of TSH, as is the
case in both iodine-deficient rats and man (Bray, 1968; Kajubi; 1975)
the initial thyroid hyperplasia may be TSH induced. It is of interest
in this respect that Young et al., (1975) found higher circulating TSH
levels in patients with iodiopathic euthyroid goitre of less than one
year's duration than in patients whose goitre had been present for
more than one year. They also found serum TSH levels to be higher in
the goitrous patients compared with control subjects, unlike the
present series, but did not measure thyroid autoantibodies and therefore
probably underestimated the incidence of autoimmune thyroiditis. It
is noteworthy that the serum TSH level was elevated in seven of the
present series of patients with diffuse thyroid enlargement. Two of
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these seven patients were available for follow-up after one year
and although the serum TSH level fell in one case, it was unchanged
in the other, raising the possibility of previously undiagnosed
dyshomonogenesis or autoimmune thyroiditis. It is considered that in
time, the diffuse non-toxic goitre of youth becomes the nodular
goitre of middle age and the autoradiographic and histological
studies of Taylor (1953; 1956; 1973) have shown that nodular goitre
is the end result of recurrent focal hyperplasia and degeneration
with the majority of nodules inactive but the functioning nodules
behaving autonomously. It would appear from the present study that
the transition from diffuse to nodular goitre is associated with a
significant reduction in serum TSH levels which may reflect the
autonomy of function of nodular goitre. The proportion of patients
with detectable serum TSH levels associated with diffuse or nodular
goitre approximates to the reported success rate in inducing goitre
shrinkage with thyroid hormone therapy (Greer and Astwood, 1953;
Astwood et al., 1960; Lamberg et al., 1960; Shimaoka and Sokal, 1974).
If the majority of patients with nodular goitre and undetectable
serum TSH levels have autonomous thyroid function, shrinkage of the
gland by exogenous thyroid hormone would not be expected.
Thyroid autonomy, in terms of lack of suppression of the radio-iodine
uptake of the thyroid gland by oral T^, has been reported in some 25%
of patients with euthyroid multinodular goitre (Werner and Spooner,
1955). Although the patients with multinodular goitre in the present
series were clinically euthyroid with normal total serum T^ levels,
a possible explanation of the reduction in serum TSH levels is that a
subgroup exists of patients with subclinical thyrotoxicosis, in whom
/
the total serum T^ levels would be raised and in whom there would be
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a lack of response of serum TSH to TRH. Evered et al., (1974) have
described raised total serum T^ levels, associated with absent serum
TSH responses to TRH, in euthyroid patients with solitary autonomous
thyroid nodules, but similar studies in patients with multinodular
goitre do not seem to have been reported.
The majority of patients with thyrotoxicosis in the present series had
undetectable levels of TSH in the serum, but 8% had levels which
were detectable between 1.8 and 5.7 mU/1. The radioimmunoassay of
TSH is therefore not sufficiently sensitive to differentiate the
euthyroid patient from the patient with thyrotoxicosis on the basis of
a single serum TSH estimation. Although a normal response of
serum TSH to TRH excludes a diagnosis of thyrotoxicosis, a lack of
response of serum TSH to the releasing hormone, invariably seen in
thyrotoxicosis, may also occur in patients with exophthalmic Graves'
disease (Lawton et al., 1971; Ormston et al., 1973) and in euthyroid
patients with solitary autonomous thyroid nodules (Evered et al., 1974).
The total serum T^ levels in these two groups of euthyroid patients may
be at the upper limit of normal or slightly raised and is an indication
of the narrow range of total serum T and T„ concentrations in which
3 4
the serum TSH response to TRH is normal (Snyder and Utiger, 1972a;
1973). This range will be much narrower for an individual patient
than the normal range of thyroid hormone levels for the population.
Furthermore, a temporary lack of response of serum TSH to TRH
occurs in patients rendered euthyroid either by iodine-131 or subtotal
thyroidectomy, as a result of the suppression of the pituitary
thyrotrophs previously exposed to high circulating T^ and T^ levels
when the patient was thyrotoxic (Chapter 6).
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In summary by estimating serum TSH by radioimmunoassay in five
hundred and eighty-one new patients referred to an Endocrine Clinic
it has been possible to:
i) define a normal range for serum TSH in patients with no
evidence of thyroid disease of <1.8-5.7 mU/1.
ii) demonstrate serum TSH levels of >20.0 mU/1 in patients with
primary hypothyroidism and therefore not only differentiate
be.tween primary and secondary hypothyroidism but also exclude
a diagnosis of primary hypothyroidism on the basis of a single
estimation of serum TSH.
iii) confirm that serum TSH levels may be normal or raised in
patients with Hashimoto's thyroiditis.
iv) demonstrate that serum TSH levels are significantly lower in
patients with simple non-toxic nodular goitre than in
euthyroid non-goitrous patients or patients with simple non¬
toxic diffuse goitre.
%
v) confirm that although serum TSH levels are undetectable in the
majority of patients with thyrotoxicosis, a single estimation
of serum TSH level will not differentiate the euthyroid from
the hyperthyroid patient.
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Fig. 1.1
Serum TSH (mU/l) levels in 581 new patients referred to the
Endocrine Clinic, Royal Infirmary, Edinburgh with suspected
thyroid disease. The upper limit of normal for the assay of
5.7 mU/1 is indicated by the horizontal continuous line. The
numbers (%) in the boxed areas represent the patients in the various
diagnostic categories with undetectable levels of TSH in the serum
of <1.8 mu/l, in addition to the euthyroid patients with serum
TSH levels in the normal range. The solid symbols represent
patients in whom circulating thyroid autoantibodies were detected.
The patient indicated by the arrow had myxoedema due to a
combination of partial failure of the pituitary and the thyroid gland.
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Fig. 1.2
Serum TSH (mU/1) levels in 52 patients with simple diffuse goitre,
63 patients with simple nodular goitre, and 191 euthyroid non-
goitrous patients. The upper limit of normal for the assay
(5.7 mU/1) is indicated by the broken line and the lower limit of
sensitivity of the assay (1.8 mU/1) by the continuous line. The
solid symbols represent patients in whom circulating thyroid
autoantibodies were detected. The serum TSH level was
undetectable in 29% of the patients with diffuse goitre, in 57% of
the patients with nodular goitre, and in 16% of the control patients.
{(from Journal of Clinical Endocrinology and Metabolism 42,
973-976, (1976)}
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Type of
goitre
No. of
patients
Mean serum TSH mU/1
(95% tolerance limits)
Diffuse
Nodular
No goitre
52
63
191
2.8 (undetectable - 7.0)
2.3 (undetectable - 5.2)
2.7 (undetectable - 5.7)
Table 1.1 Serum TSH levels in goitrous and non-goitrous patients.
The levels in the patients with nodular goitre were
significantly lower than those recorded either in the
patients with diffuse goitre (P <0.01) or in the
patients without goitre (P<0.0001).
{(from Journal of Clinical Endocrinology and Metabolism,
42, 973-976 (1976) }
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CHAPTER 2 A comparison of the serum TSH level and the TSH
stimulation test in patients with suspected
hypothyroidism.
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The use of a TSH stimulation test to differentiate between primary
and secondary hypothyroidism was suggested almost forty years ago
(Thompson et al., 1936: Scowen 1937). The report of an increase in
the radioiodine uptake by the thyroid gland after the intramuscular
administration of bovine TSH (BTSH) to normal subjects (Stanley and
Astwood, 1949) formed the basis of the present-day TSH stimulation
test. Such a test has been widely used in clinical practice, not
only to separate the euthyroid patient with a normal reserve of
thyroid function from the euthyroid patient with an impaired reserve
of thyroid function and from the patient with primary hypothyroidism,
but also to identify the occasional patient with hypothyroidism
secondary to disease of the anterior pituitary gland or
hypothalamus. The procedure for the TSH stimulation test has varied
both in regard to the form of radioiodine uptake and to the dose and
duration of administration of BTSH. Most centres have employed a
single dose TSH stimulation test (Jefferies et al., 1953:
Bishopric et al., 1955: Fletcher and Besford, 1957: Friis et al., 1959)
or a test utilising three daily injections of BTSH (Querido and
St&nbury 1950: Perloff et al., 1951: Schneeberg et al., 1954). In all
series the tracer dose of radioiodine has been administered some
eighteen hours after the last or sole dose of BTSH when the effect on
the radioiodine uptake by the thyroid gland is at a maximum, although
the doses of BTSH given have exceeded that required for a maximal
increase in uptake (Einhorn and Larssen, 1959). More recent studies
comparing various dosage regimens of BTSH to determine which gives the
most effective stimulation for the clinical evaluation of thyroid
function indicated that a single dose test of 5 USP units BTSH would
differentiate in most instances the normal subject from the patient
/
with primary hypothyroidism or the euthyroid patient with impaired
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reserve of thyroid function observed most commonly after iodine-131
treatment of thyrotoxicosis (Jefferies et al., 1956). The
identification of the patient with thyroid failure due to
disordered pituitary or hypothalamic function may require a three
day stimulation test to be performed (Taunton et al., 1965: Burke, 1968).
The availability of a sensitive radioimmunoassay for TSH (Odell et al.,
1965: Utiger, 1965) and the demonstration of raised levels of TSH
in the serum of patients with primary hypothyroidism or in euthyroid
patients -with impaired reserve of thyroid function and of low or
normal levels of serum TSH in patients with secondary hypothyroidism
(Odell et al., 1967b: Hedley et al., 1971a: Hershman and Pittman, 1971:
Mayberry et al., 1971: Slingerland et al., 1972) should allow the
distinction to be made between primary thyroid failure and secondary
hypothyroidism without recourse to the TSH stimulation test.
The purpose of the present study was to test this hypothesis by
estimating the serum TSH level and performing the TSH stimulation
test in patients referred to a thyroid clinic with suspected hypo¬
thyroidism. Since the TSH stimulation test is time-consuming for
both patients and technical staff and is not without side-effects,
although minor (Einhorn 1958), it would be a distinct advantage
to replace the stimulation test by the measurement of a single
serum TSH level.
In addition, by estimating serum TSH levels before and after the
administration of BTSH in patients with primary hypothyroidism, it is
possible to test whether a "short-feedback" of TSH on the
hypothalamus exists in man. Several studies have indicated that
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pituitary hormones may control their own secretion by regulating
at the hypothalamic level the synthesis and release of their
hypothalamic factors (Motta et al., 1969). If a negative "short-
feedback" of TSH is present in man, the raised serum TSH levels
of untreated primary hypothyroidism should fall markedly after the
administration of BTSH which shares the biological, but not the
immunological, properties of TSH.
PATIENTS AND METHODS
The subjects were one hundred and twenty-seven consecutive patients
seen at the Endocrine Clinic, Royal Infirmary, Edinburgh, in whom
it was necessary to confirm or exclude a diagnosis of hypothyroidism.
The final diagnosis was made from clinical examination and from
estimations of serum protein-bound iodine (Simpson, 1967) and total
serum thyroxine by competitive protein-binding analysis (Seth, 1973) ,
augmented when necessary by serum cholestrol, electrocardiograph
and ankle reflex time, as well as the patient's response to
replacement therapy with thyroxine. Patients on thyroid
replacement therapy were excluded.
There were fifty-one euthyroid patients. Thirty-three were
referred by their general practitioners with suspected hypothyroidism
and five of these had a goitre. The other eighteen patients had
previously attended the Endocrine Clinic; eight had received iodine-131
therapy and two had been treated by subtotal thyroidectomy for
thyrotoxicosis; four had idiopathic Addison's disease, two had
hypopituitarism and two had pernicious anaemia with thyroid antibodies
in the serum. There were seventy-six patients with primary
26
hypothyroidism, of whom thirteen had spontaneous hypothyroidism
and had been referred by their general practitioners; fifty-six had
been previously treated with iodine-131 and seven had undergone
subtotal thyroidectomy for thyrotoxicosis.
Blood was withdrawn from each patient for the estimation of serum
TSH by a sensitive double antibody radioimmunoassay as previously
described in which the upper limit of normal is 5.7 mti/1. The 4
hour uptake of iodine-132 by the thyroid gland was then measured
before the administration of BTSH (Thytropar) 10 international
units intramuscularly at 16.OO hours on three consecutive days,
and was repeated on the day following the last injection. In
twenty-four of the patients with primary hypothyroidism the serum
TSH level was also estimated eighteen hours after the last injection
of BTSH and in three of the patients with primary hypothyroidism the
serum TSH level was estimated at 7, 15, 25, 30 (two patients only),
45, 60, 90 (two patients only), 120 and 180 minutes after the first
intramuscular injection of BTSH.
Antibodies to thyroid cytoplasm were detected by the indirect
immunofluorescence technique using sections of human thyroid
tissue and by complement fixation using a saline extract of human
thyroid (Doniach and Roitt, 1975).
RESULTS
The levels of serum TSH correlated with the final diagnosis and
the results of the TSH stimulation test are shown in Fig. 2.1.
/
Combining all the euthyroid patients in the present series, an
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attempt was made to define more precisely the limits of normal in
the TSH stimulation test by determining the figure which correlated
best with the serum TSH levels i.e. that as few patients as possible
were defined as having a normal serum TSH level and an abnormal
TSH stimulation test. On this basis, the normal absolute increase
in the thyroid gland uptake of iodine-132 at 4 hours, following 10 i.u.
BTSH i.m. on each of three consecutive days, was 13% or more.
All seventy-six patients with primary hypothyroidism must by
definition be considered to have an abnormal TSH stimulation test,
and the greatest absolute increase in the 4 hour iodine-132 uptake by
the thyroid gland after TSH stimulation was 8% i.e. 22-30%. The
serum TSH level was markedly raised in all the patients with primary
hypothyroidism, ranging from 26-537mU/l«
The euthyroid patients could be subdivided into four groups on the
basis of the result of the serum TSH estimation and the TSH
stimulation test.
(i) Normal TSH stimulation test and normal serum TSH level:
There were twenty-eight patients in this category, of whom
only one, who had been treated with iodine-131 for thyro¬
toxicosis, had a previous history of thyroid disease. A
simple non-toxic goitre was present in four of the patients
and one patient had partial hypopituitarism.
(ii) Abnormal TSH stimulation test and elevated serum TSH level:
The eight patients in this group had serum TSH levels of
6.4-93.5mU/l. With the exception of the patient with partial
hypopituitarism, the patients had antibodies to thyroid
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microsomes. Six of the patients had been treated with iodine-
131 or subtotal thyroidectomy for thyrotoxicosis.
(iii) Normal TSH stimulation_test_but_elevated_serum_TSH_level:
This group comprised eleven patients. The two highest
serum TSH levels of 48.4 and 25.3 mU/1 respectively, were
found in a patient who had been treated with iodine-131 for
thyrotoxicosis and in a patient considered to have
Hashimoto's thyroiditis. Circulating thyroid antibodies
were present in five of the other nine patients with elevated
serum TSH levels.
(iv) Abnormal TSH stimulation test but normal serum TSH level:
There were only four patients in this category, of whom two
had previously been treated with radioactive iodine for
thyrotoxicosis (15-19%; 24-30%). The remaining two
patients with TSH stimulation test results of 13-21% and
19-27% respectively, had not received previous therapy
directed at the thyroid gland.
The results of the 4 hour iodine-132 uptake tests by the thyroid gland
and the serum TSH levels before and after BTSH 10 i.u. i.m. daily
for three consectuive days in the twenty-four patients with primary
hypothyroidism are shown in table 2.1. The mean serum TSH level
±S.E. before the TSH stimulation test was 87.3±11.2mU/l and
84.7+11.4mU/l after the TSH stimulation test. The serum TSH
level fell in thirteen of the patients, the maximum percentage
decrease being 33% (69-45mU/l), but rose in the other eleven patients,
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the maximum percentage increase being 31% (27-36mU/l).
The serum TSH levels before and for three hours after the
administration of 10 i.u. i.m. BTSH to three patients with primary
hypothyroidism are illustrated in Fig 2.2. None of the three patients
showed a fall in the level of serum TSH after exogenous BTSH injection.
DISCUSSION
The TSH stimulation test and the serum TSH level are both employed
as tests of reserve of thyroid function. Whereas the TSH
stimulation test measures the capacity of the thyroid gland to
respond to the stimulus of exogenous BTSH by an increase in the uptake
of iodine, the serum TSH level is related to the concentration of thyroid
hormones presented to the thyrotrophs of the anterior pituitary gland.
Although the two tests therefore assess different aspects of thyroid
function there was a correlation between the tests in one hundred and
twenty-two of the one hundred and thirty-seven patients in the present
series, in that a normal TSH stimulation test was associated with a
normal serum TSH level or an abnormal TSH stimulation test with an
elevated serum TSH level whether the patient was euthyroid or had
primary hypothyroidism. It has long been recognised that an abnormal
TSH stimulation test can occur in euthyroid patients, usually after
destructive therapy to the thyroid gland for thyrotoxicosis, and can
persist for many years without the development of hypothyroidism
(Jefferies et al. , 1956). Six of the eight euthyroid patients with
an ' abnormal TSH stimulation test and a raised serum TSH level in the
present series had been treated in the past with iodine-131 or sub¬
total thyroidectomy, and it is of interest that raised serum TSH levels,
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like abnormal TSH stimulation tests, have been shown to remain
elevated in euthyroid patients for some years without the development
of hypothyroidism (Slingerland et al., 1972; Toft et al., 1975).
The demonstration of eleven euthyroid patients with normal reserve
of.thyroid function on the basis of the TSH stimulation test, but
with some degree of thyroid failure as indicated by a raised serum
TSH level is presumably explained by the pharmacological stimulus of
BTSH used in this study, masking a minor degree of impaired thyroid
function. If such a hypothesis is true, the measurement of serum
TSH is a more sensitive index of thyroid failure than the TSH
stimulation test.
The remaining four patients in the series, all of whom were
euthyroid, had a TSH stimulation test result and a serum TSH
level which were at variance, in that an abnormal TSH stimulation
test indicative of thyroid failure, was associated with a normal
serum TSH level which in the absence of pituitary or hypothalamic
disease is an indication of normal thyroid function. Two of these
four patients had been previously treated with iodine-131 for
thyrotoxicosis and it is possible that the thyroid remnant was
functioning autonomously and was therefore unresponsive to BTSH.
If such an explanation is valid, the measurement of serum TSH is a
more meaningful expression of thyroid status than the TSH stimulation
test in patients who have been previously treated with iodine-131 and
presumably subtotal thyroidectomy for thyrotoxicosis in the past.
In the two remaining patients no explanation can be offered for the
anomalous combination of an abnormal TSH stimulation test and a
normal serum TSH level, but it is of interest that Nelson et al.,(1972)
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described a similar group of patients all of whom had either a simple
non-toxic goitre or who had been treated with iodine-131 for
thyrotoxicosis.
The present study has shown that the estimation of a single serum TSH
level is a better index of reserve of thyroid function than the time-
consuming TSH stimulation test, and the sole use of the TSH
stimulation test must be to assess whether a patient, empirically
started on thyroxine replacement therapy in the past, requires to
continue .taking such treatment on a life-long basis.
The lack of reduction in the high serum TSH levels in patients with
untreated primary hypothyroidism despite the presence of high
BTSH levels in the serum lasting twenty-four hours in such
patients after the administration of exogenous BTSH (Hershman and
Edwards, 1972) is evidence against the negative "short-feedback"
of TSH on the hypothalamus in man.
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Fig. 2.1
Serum TSH levels (mU/1) correlated with diagnosis and results of TSH
stimulation tests in 127 consecutive patients investigated for
suspected hypothyroidism. The horizontal line represents the
upper limit of normal for the TSH assay (5.7mU/l).
O - post iodine-131;d-post thyroidectomy; V - spontaneous primary
hypothyroidism;A - untreated euthyroid; + - hypopituitarism without
antibodies in the serum. Solid symbols indicate that thyroid
cytoplasmic antibodies were present in the serum.
{adapted from Clinical Endocrinology, 2135-139 (1973)}
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Fig. 2.2
Human serum TSH levels in three patients with untreated primary
hypothyroidism in response to 10 i.u. bovine TSH intramuscularly;
the arrow indicates the time of injection.
{from Journal of Endocrinology, 59, 189-190 (1973)}
34
500
400
CO
300
3
u
o
CO 200
100
0
-15 0
Time in minutes
Category and case 4 hour iodine-132 uptake
by thyroid gland (%)
HTSH mu/l
pre BTSH post BTSH pre BTSH post BTSH
Idiopathic
1 14
2 5
Post subtotal thyroid¬
ectomy
3 7
4 11
5 14
6 10
iod_ine-131
7 11
8 22
9 12
10 16
11 16
12 17
13 8
14 7
15 12
16 7
17 16
18 7
19 24
20 11
21 5
22 13
23 9
24 14
22 210 221
3 167 184
9 122 138
14 96 112
9 203 197
11 43 50
9 41 36
30 74 75
9 195 168
15 44 42
16 76 63
16 115 83
11 74 64
7 44 47
7 70 45
8 93 86
16 44 45
7 101 87
10 44 38
11 27 36
4 62 61
14 37 46
8 51 53
9 65 58
Table 2.1 Results of 4 hour iodine-132 uptake tests by the thyroid
gland and human serum TSH (HTSH) levels before and after
bovine TSH (BTSH) daily for 3 days in twenty-four
patients with primary hypothyroidism.
{from Journal of Endocrinology, 59, 189-190 (1973)}
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CHAPTER 3 Serum TSH response to TRH in euthyroid patients and
in patients with thyroid disease.
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It has been established for many years that the hypothalamus controls
the release of TSH from the anterior pituitary gland by means of
neurohumoral substances (Harris, 1955), but the first unequivocal
demonstration of the presence of a factor in hypothalamic tissue with
TSH-releasing activity was not reported until the early 1960's
(Gqillemin et al., 1962; Schreiber et al., 1962; Guillemin et al.,
1963). The TSH-releasing factor (TRF) was purified from hypothalamic
tissue from a number of sources including sheep, pig, cow and man and
its biological activity demonstrated by means of both in vitro and in
vivo studies (Guillemin et al., 1965; Schally et al., 1966a and 1966b;
Schally et al., 1967). Schally and his colleagues (1966a) also
demonstrated that the peptide fragment of porcine TRF contained three
amino-acids, histidine, glutamic acid,and proline, and suggested that
TRF be renamed thyrotrophin-releasing hormone (TRH) (Schally et al.,
1968). It was subsequently established by the same group of workers
(Schally et al., 1969) that the amino acid sequence was glutamic
acid-histidine-proline although the simple tripeptide had no
biological activity. Various synthetic sequences of the three amino
acids were studied and it was found that L-pyroglutamyl-L-histidyl-L-
proline-amide had the full biological activity of the isolated TRH
(Burgus et al., 1969; Folkers et al., 1969; Gillessen et al., 1970)
and was chemically identical (Burgus et al., 1970; Nair et al., 1970)
The rise in serum TSH in response to intravenous TRH in normal man
(Bowers et al., 1970; Fleischer et al., 1970; Hall et al., 1970b;
Hershman and Pittman, 1970; Ormston et al., 1971a) was anticipated
from the previous observation that serum TSH levels increased when
a highly purified porcine preparation of the releasing hormone was
given to cretins (Bowers et a., 1968a). It was Ormston et al.,(1971b)
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however, who defined the serum TSH response to intravenous synthetic
TRH in a large number of euthyroid subjects and patients with
thyrotoxicosis and primary hypothyroidism. The measurement of
serum TSH before and at twenty and sixty minutes after 200pg TRH
is now widely used in the United Kingdom as a thyroid function test.
TRH has since been shown to cause the release of prolactin (Bowers et
al. , 1971; Jacobs et al., 1971; L'Hermite et al., 1972; Toft et al. ,
1973b) follicle stimulating hormone in the male (Mortimer et al., 1973)
and growth hormone in patients with acromegaly (Irie and Tsushima,
1972), but the physiological significance of these findings is in some
doubt.
The purpose of the present study was to establish the normal range for
the serum TSH response to TRH in patients with no evidence of thyroid
disease, and to measure the response in patients with primary hypo¬
thyroidism, in euthyroid patients with serum TSH levels close to the
upper limit of normal of 5.7mU/l, and in patients with thyrotoxicosis.
PATIENTS AND METHODS
Serum TSH was estimated before and at twenty and sixty minutes after
the single administration of 200 yg TRH as a rapid intravenous injection
in the following groups of patients.
(i) Seventy-four new patients (59 females, 15 males) referred to
the Endocrine Clinic with suspected thyroid disease, but in
whom no evidence of thyroid dysfunction could be found.
The mean age of the patients was thirty-nine years (range
16-77 years). The serum TSH level lay within the normal
range of <1.8-5.7mU/l in each patient. The normal range of
38
the response of serum TSH to 200 yg TRH intravenously was
calculated from the results obtained in this group of
patients.
(ii) Forty-nine patients (44 females, 15 males) with a mean age
of fifty-three years (range 21-79 years) in whom a diagnosis
of primary hypothyroidism was made. The diagnosis in each
case was made clinically and on the basis of a low total
serum T^ measured by competitive protein-binding analysis
-(Seth, 1973), a low ETR (Thorson et al. , 1972; Toft et al.,
1973a), a lack of response of the 4 hour iodine-132 uptake
by the thyroid gland following the intramuscular injection of
lO i.u. bovine TSH for three consecutive days, and a raised
serum TSH level. Fifteen of the patients had spontaneous
primary hypothyroidism, thirty-one had been treated with
iodine-131 and three by subtotal thyroidectomy for
thyrotoxicosis.
(iii) Ten patients (4 females, 6 males) with a mean age of forty-
two years (range 15-55 years) who were clinically and
biochemically euthyroid but in whom the serum TSH level was
found to be at the upper limit of normal or minimally elevated.
In three of these patients there was no evidence, past or
present, of thyroid disease, although circulating autoantibodies
against thyroid microsomes were detected by immunofluorescence
in one patient. Two patients had Hashimoto's thyroiditis,
two had been treated by subtotal thyroidectomy and two with
iodine-131 for thyrotoxicosis. The remaining patient in this
/
group had received radiotherapy to the head and neck for
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reticulum cell sarcoma three years earlier.
(iv) Sixty-three patients (46 females, 17 males) with a mean age
of forty-eight years (range 21-77 years) who had
thyrotoxicosis. The diagnosis of thyrotoxicosis was made
clinically and on the basis of a raised total serum
thyroxine and ETR and an increased 4 hour uptake of
iodine-132 by the thyroid gland which was repeated in some
cases after the oral administration of 120 pg daily for
• seven days.
RESULTS
(i) Patients_with_no_evidence_of_thyroid_disease:
The mean serum TSH level (range) before and at twenty and
sixty minutes after 200 pg TRH intravenously in the fifty-nine
female patients with no evidence of thyroid disease was
2.7 (<1.8-5.6); 12.0 (3.9-25.3) and 9.3 (3.0-24.4) mU/1
respectively, and in the fifteen male patients in the same
category, 2.8 (<1.8-5.0); 10.5 (6.6-22.5) and 8.2 (4.7-19.0)
mU/1 respectively. Although the mean serum TSH level at
twenty and sixty minutes after the administration of TRH in
the females was greater than in the males, the differences
were not significant (P >0.05 in each case). There was no
apparent relationship between serum TSH response to TRH and
the age of the patient. The mean serum TSH (range) before
and at twenty and sixty minutes after TRH in the total
seventy-four patients was 2.7 (< 1.8-5.6); 11.7 (3.9-25.3)
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and 9.1 (3.0-24.4) mu/l. The range of response in these
total seventy-four patients, referred to the Endocrine Clinic
with suspected thyroid disease but in whom no evidence of
thyroid dysfunction was found, was considered as the normal
range and is represented graphically in Fig. 3.1.
(ii) Patients with primary hypothyroidism:
The mean basal serum TSH level (range) in the forty-nine
patients with untreated primary hypothyroidism of 82.3
•(23.2-614) increased to 177.8 (45.6-830) and 174.4
(27.6-1175) mU/1 respectively at twenty and sixty minutes
after the injection of TRH, and is represented graphically
in Fig. 3.2 in relation to the normal range. There was no
overlap of the serum TSH response to TRH with a normal range
in any patient with primary hypothyroidism. In all but
fourteen of the patients the serum TSH level was higher at
twenty minutes than the level at sixty minutes after TRH.
(iil) Euthyroid patients with serum TSH levels at the upper limit
or minimally elevated:
The serum TSH responses to TRH in the ten euthyroid patients
with basal serum TSH levels at the upper limit of normal of
5.7mU/l or slightly elevated are shown in Table 3.1. The
normal response of serum TSH to TRH in patients 1-3 suggests
that these three patients have a normal brain-thyroid axis
and that the basal serum TSH levels of 5.7, 6.7 and 6.9mU/l
should be regarded as normal. In patients 4-10 there was
an enhanced response to serum TSH to TRH similar to that
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seen in the patients with primary hypothyroidism. The
serum TSH levels of 5.9-8.8mU/l in these patients are
presumably an indication of impaired reserve of thyroid
function, and it is of interest that an aetiological
factor existed to account for the raised basal serum TSH
level in each case.
(iv) Patients with thyrotoxicosis:
The basal serum TSH level was undetectable at less than
1.8mU/l in fifty-six (89%) of the sixty-three patients with
thyrotoxicosis and remained undetectable in fifty-five of the
patients. In four patients the basal serum TSH levels of
2.0, 2.1, 2.2 and 2.3mU/l respectively, either fell or
remained unchanged after TRH administration. In a further
four patients with basal serum TSH levels of <1.8, 1.9, 1.9
and 2.0mU/l there was a slight rise in serum TSH levels to
2.2, 2.1, 2.4 and 2.5 mU/1 at twenty minutes and to 2.0,
2.0, 2.2 and 2.1mU/l at sixty minutes after the injection of
TRH. The maximum response of serum TSH to TRH, therefore,
in a patient with thyrotoxicosis was from 1.9 to 2.4mU/l, an
increase of 0.5mU/l.
If the serum TSH level had been measured only before and at twenty
minutes after TRH each patient in the present study would have
remained in the same TSH response category, and therefore in the
absence of pituitary or hypothalamic disease, sampling of the serum
TSH level at sixty minutes after the injection of TRH in patients with
suspected thyroid disease is probably of little value.
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DISCUSSION
The normal range of serum TSH response to TRH in the present series
was calculated from the results obtained in patients referred to an
Endocrine clinic with suspected thyroid disease but in whom no
evidence of thyroid dysfunction was found. Applying the
/
epidemiological arguments expressed in Chapter 1 for the calculation
of the normal range for basal serum TSH levels, it is felt that a
normal range determined on this basis is more acceptable than one
based on results obtained in healthy volunteers or hospital in-patients.
The mean"serum TSH levels at twenty and sixty minutes after TRH were
lower in the female patients than in the male patients, but unlike the
report of Ormston et al., (1971b) the differences were not
significant which may be a consequence of the small number of male
patients. On the other hand, Snyder and Utiger (1972b) were unable
to demonstrate a greater magnitude of serum TSH response to 400yg
TRH in females aged 20-39 years than in males when matched for age,
height and weight, but it is possible that the larger dose of TRH
used in this study masked any sex difference. There are similarly
conflicting views of the effect of exogenous oestrogen in males on
the serum TSH response to TRH. Fagliaetal., (1973) found that
oestrogens caused an increased response of serum TSH to lOOyg TRH,
but Gual et al., (1972) were unable to show any augmentation of the
serum TSH response to 500yg TRH in males treated with ethinyl
oestradiol. A diminishing serum TSH response to TRH with
increasing age in man has been reported (Snyder and Utiger, 1972b)
but this was not apparent in the present study.
Serum TSH levels in patients with untreated primary hypothyroidism
have been shown to be in excess of 20.0mU/l using the current
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radioimmunoassay system, and since a single estimation of serum TSH
will differentiate the euthyroid patient from the patient with
primary hypothyroidism, the TRH test is of no added value in the
investigation of suspected primary hypothyroidism. It should be
noted, in addition, that a raised serum TSH level will be
associated with an enhanced response to TRH in euthyroid patients
with impaired reserve of thyroid function. The TRH test would
appear to be of value, however, in determining whether a serum TSH
level, which approximates to the upper limit of normal for the assay,
is normal- or elevated. If it can be assumed that a normal serum
TSH response to TRH, despite a slightly raised basal serum TSH level,
is indicative of a normal brain-thyroid axis, the TRH test will
identify patients with minor degrees ' of thyroid failure. Such
patients may develop hypothyroidism in the future and are certainly
at an increased risk of hypothyroidism after iodine-131 therapy for
thyrotoxicosis than patients with a normal serum TSH level (Toft et
al., 1975). The seven patients with borderline raised levels of
serum TSH in the present study and augmented responses to TRH
each had an aetiological factor on which to explain the minor
degree of thyroid failure such as surgical or radioiodine treatment of
thyrotoxicosis, autoimmune thyroid disease, or the more recently
recognised external irradiation of the neck for malignant disease
(Glatstein et al., 1971).
A single estimation of serum TSH, in contrast to its value in the
diagnosis of primary hypothyroidism, does not differentiate between
the euthyroid and hyperthyroid patient. The serum TSH level does
not rise, however, after the intravenous administration of TRH, unless
very large doses of TRH are given (Hershman and Pittman, 1970).
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On account of the sensitivity of the thyrotrophs of the anterior
pituitary gland to changes in circulating thyroid hormone levels
within the normal range, a lack of response of serum TSH to TRH
may occur in euthyroid patients in whom levels of total serum and
are elevated for the individual but still within the accepted normal
range, as in many of the patients with exophthalmic Graves' disease,
solitary autonomous thyroid nodules and in those patients on long-term
suppressive or replacement therapy with thyroxine. Like the
suppression test, therefore, the major role of the TRH test is in the
investigation of patients with suspected thyrotoxicosis in whom
clinical examination and biochemical results are equivocal. A
normal serum TSH response to TRH excludes the diagnosis of
thyrotoxicosis, whereas an absent response is compatible with such a
diagnosis. With the possible exception of the investigation of
patients with secondary hypothyroidism, the estimation of the serum
TSH level sixty minutes after TRH appears unnecessary and it is
suggested that serum TSH levels are only measured before and at twenty
minutes after 200pg TRH intravenously and as such this valuable
additional test of thyroid function can be performed readily at an
out-patient clinic attendance.
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Fig. 3.1
Mean and range of serum TSH levels before and at twenty and sixty
minutes after 200pg TRH intravenously in seventy-four patients
(59 females, 15 males) referred to the Endocrine Clinic, Royal
Infirmary, Edinburgh with suspected thyroid disease but in whom no
evidence of thyroid dysfunction could be found.
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Fig. 3.2
Mean and range serum TSH levels before and at twenty and sixty minutes
after 200P3 TRH intravenously in forty-nine patients with untreated
primary hypothyroidism and mean serum TSH levels before and at
twenty and sixty minutes after 20Cyg TRH intravenously in sixty-
three patients with thyrotoxicosis. The normal range is shown for
comparison.
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20'
60'
1
61
F
5.7
8.6
2.0
Nohistoryfthyroiddisease.
2
50
F
6.7
25.0
18.4
Subtotalthyroidectomyf r thyrotoxicosis,1964.
3
36
F
6.9
11.4
8.3
Nohistoryfthyr iddisease.
4
16
F
5.9
48.0
25.6
Hashimoto'sthyroiditis.
5
55
F
6.5
37.0
26.0
Thyroidautoantibodies.
6
51
F
6.9
52.4
40.3
Iodine-131forthyrotoxicosis,1957
7
42
F
7.7
38.2
r—1
i—1
CO
Hashimoto'sthyroiditis.
8
55
F
8.6
»61.0
55.7
Irradiationtohe danneckf r reticulumcellsarcoma,1971.
9
39
M
8.7
55.8
35.6
Subtotalthyroidectomyf r thyrotoxicosis,1958.
10
61
F
8.8
63.5
58.0
Iodine-131forthyrotoxicosis,1970
Table3.1
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CHAPTER 4 A comparison of the serum TSH response to TRH and
the T suppression test in patients with suspected
thyrotoxicosis.
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The demonstration that thyroid extract or thyroxine reduced the
radioiodine uptake by the thyroid gland in normal subjects (Stanley
and Astwood, 1949; Greer, 1951; Morgans et al., 1951) but not in
patients with thyrotoxicosis (Werner et al., 1952; Greer and Smith,
1954) led to the development of the suppression test (Werner and
Spooner, 1955). Subsequently, the suppression test became
widely used in attempting to differentiate between the patient with
thyrotoxicosis and the euthyroid patient with equivocal tests of
thyroid function. Although the conditions of the test varied from
centre to centre, with repsect to form of radioiodine uptake, dosage
and duration of administration of T^, it became apparent that it
effectively discriminated between the euthyroid and thyrotoxic patient
in most instances (Perlmutter and Slater, 1955; Dresner and
Schneeberg, 1958; Hobbs et al., 1963: Kristensen et al., 1963;
Friis, 1963; Burke, 1967; Bayliss, 1967). Lack of suppression of
radioiodine uptake by T^ did not invariably indicate thyrotoxicosis,
however, and was noted in a proportion of euthyroid patients with
multinodular goitre (Werner and Spooner, 1955) and with exophthalmic
Graves' disease (Werner, 1955; Bowden and Rose, 1969; Hall et al.,
1970a) and following successful treatment of thyrotoxicosis with
radioiodine or surgery (Werner 1956). Despite its undoubted value,
the suppression test has the disadvantage of being time-consuming
for patients and technical staff, of involving two radioisotope tests
and of possibly precipitating a cardiac dysrhythmia in the older
patient with ischaemic heart disease.
The demonstration that a rise in serum TSH occurs following the
intravenous injection of TRH in euthyroid individuals (Hall et al.,
1970b; Bowers et al., 1970; Fleischer et al., 1970; Hershman and
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Pittman, 1970) but not in patients with thyrotoxicosis (Ormston et al.,
1971b) introduced a further test of thyroid function which could be
used in the differentiation of the euthyroid from the hyperthyroid
state.
There are two factors which are common to all cases of thyrotoxicosis;
namely, that the thyroid gland is outwith the control of pituitary
TSH, and that the levels of T^ and/or are invariably raised. The
T^ suppression test indicates dependence or independence of the
thyroid gland upon pituitary TSH, whereas the serum TSH response to
TRH is a measure of whether excess thyroid hormone is present in
the circulation. It is, therefore, conceivable that the T^
suppression test which has been widely used for almost twenty years
could be replaced by the less inconvenient TRH test as a test of
thyroid function in patients with suspected thyrotoxicosis, and the
purpose of the present study was to test this hypothesis.
PATIENTS AND METHODS
Forty-one consecutive patients (30 females, 11 males) were studied
who had been referred to the Endocrine Clinic with suspected
thyrotoxicosis and in whom there was no past history of thyroid
disease. The mean age was 45 years (range 20-70 years). Thyroid
status was determined by clinical examination and by the estimation
of the total serum T^ by competitive protein-binding analysis
(Seth, 1973), the ETR (Toft et al., 1973a) and by the measurement of
the 4 hour uptake of iodine-132 by the thyroid gland. Nineteen of
the patients were thyrotoxic, and the remaining 22 patients euthyroid.
In 3 of these euthyroid patients a diffusely enlarged simple goitre
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was present, and a further 4 patients had exophthalmic Graves'
disease.
Immediately after the initial 4 hour uptake of iodine-132 by the
thyroid gland had been measured, the serum TSH level was estimated
before and at twenty and sixty minutes after the intravenous
administration of 200yg TRH. Oral in a dose of 40yg eight-hourly
was then given for seven days and the radioiodine uptake by the
thyroid gland repeated.
RESULTS
The percentage fall in the initial 4 hour uptake of iodine-132 by the
thyroid gland after oral T^ 120yg daily for seven days is expressed
in relation to the serum TSH response to TRH in fig. 4.1. All 19
patients with thyrotoxicosis and 3 of the 4 patients with
exophthalmic Graves' disease had either no response or a rise of
serum TSH of less than 0.5mU/l after TRH. In 8 of these patients
there was either no suppression of the radioiodine uptake or the
second uptake was greater than the first, whereas in the remaining
14 patients with a lack of response of serum TSH to TRH the
suppression of the initial radioiodine uptake ranged from 2-32%.
In the 19 patients in whom there was a rise of more than 0. .5>mU/l
in the serum TSH level in response to TRH, there was a fall of
between 30-82% of the initial 4 hour uptake of iodine-132 by the
thyroid gland following T^ suppression. There was no apparent
relationship between the degree of thyroidal suppression and the rise
in serum TSH in response to TRH.
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DISCUSSION
The present study has demonstrated that a lack of response of the
serum TSH level to TRH is associated with suppression of the
initial radioiodine uptake by the thyroid gland by oral T^ of<32%,
whereas a rise in serum TSH level in response to TRH is associated
with suppression of the radioiodine uptake of > 30%. It
would appear, therefore, that the TRH test which is convenient to
doctor and patient and is free of major side-effects can replace the
time-consuming and potentially dangerous T^ suppression test in
the investigation of patients with thyrotoxicosis. It should be
borne in mind that a lack of response of the serum TSH level to TRH
or a failure to demonstrate thyroid suppressibility with oral T^ is
not necessarily an indication of the presence of hyperthyroidism. In
three of the four patients with exophthalmic Graves' disease an
absent serum TSH response to TRH was associated with a lack of
suppression of the radioiodine uptake by the thyroid gland after T^»
confirming the earlier observations by Lawton et al., (1971) and
Ormston et al., (1973). The authors detected total serum T^ levels
in such patients to be at the upper limit of normal or frankly
elevated, although not in the range usually encountered in
thyrotoxicosis. The lack of response of the serum TSH level to TRH
in a proportion of patients with exophthalmic Graves' disease, who are
by definition euthyroid (Rundle and Wilson, 1945), is an indication
of the sensitivity of the pituitary thyrotroph to minor changes in the
levels of circulating thyroid hormones (Snyder and Utiger, 1972a).
The thyroid autonomy, if present, in patients with exophthalmic
Graves' disease may in the future be shown to be related to the
presence in the serum of TSH receptor antibodies.
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Since the TRH test is a measure of the effect of circulating levels
of thyroid hormones at the level of the anterior pituitary gland
and the suppression test is a measure of thyroid autonomy, it is
possible that in certain circumstances the correlation between the two
tests of thyroid function demonstrated in the present study will not
hold. Thyroid autonomy as assessed by the effect of oral on the
uptake of radioiodine has been shown to be present in 50% or more of
euthyroid patients previously treated with iodine-131 for thyro¬
toxicosis, and in a lesser proportion of those rendered euthyroid by
subtotal thyroidectomy (Werner, 1956; Hedley et al., 1971b). The
ratio of normal to abnormal suppression tests depends on the time
which has elapsed since treatment of the thyrotoxicosis (Werner,
1956). The frequency with which detectable TSH receptor antibodies
have been found in patients with thyrotoxicosis treated by iodine-131
or subtotal thyroidectomy is similar to the frequency with which
thyroid autonomy of the thyroid remnant has been demonstrated by the
T^ suppression test (Mukhtar et al., 1975). It is likely that lack
of suppression of the radioiodine uptake by the thyroid gland is a
function of the presence of TSH receptor antibodies in the serum which
may be found in euthyroid patients with no history of thyroid disease
or in those who have been previously treated for thyrotoxicosis. The
total serum T^ and T levels in such patients will be normal and3 4
therefore the serum TSH response to TRH will be normal or even
exaggerated, despite the demonstration of thyroid autonomy. It is
well recognised that a lack of suppression of the radioiodine uptake
by T^ may occur in euthyroid patients with multinodular goitre
(Werner and Spooner, 1955; Kristensen et al., 1963; Friis, 1963) due
to autonomous function of one or more of the thyroid nodules.
/
Although serum TSH levels have been shown to be significantly lower in
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patients with multinodular goitre than in patients with diffusely
enlarged simple goitre of euthyroid controls (Chaper 1), there does
not appear to be a published study of the correlation of the TRH
test and the suppression test in patients with multinodular goitre.
It is possible that a lack of correlation may exist in some patients,
in whom the autonomous thyroid tissue is not secreting sufficient
thyroid hormones to suppress the pituitary thyrotrophs.
In conclusion, with the exception of patients in the early weeks after
iodine-131 or subtotal thyroidectomy for thyrotoxicosis when the
pituitary thyrotrophs are still suppressed (Sanchez-Franco et al., 1974;
Toft et a., 1974b), a lack of response of the serum TSH level to
TRH implies that the patient is thyrotoxic or that the levels of
T^ and/or T^ in the serum are inappropriately high for the
individual despite being in the accepted normal ranges. The
euthyroid patient with a lack of serum TSH response to TRH may be at
risk of developing thyrotoxicosis in the future, and if this proves to
be the case, valuable information has been gained from performing the
test. The disadvantages of the T^ suppression test are numerous and
have been stated and as a test of thyroid function in patients with
suspected thyrotoxicosis it should be abandoned in favour of the TRH
test. The loss of a test of thyroid autonomy is of little clinical
significance and it is conceivable that the detection of TSH
receptor antibodies in the serum will correlate with thyroid autonomy
and might prove to be of some predictive value as regards relapse of
thyrotoxicosis especially in the patient being treated with antithyroid
drugs.
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Fig. 4.1
The percentage fall in initial 4 hour uptake of iodine-132 by the
thyroid gland after oral 120yg daily for seven days in relation to
the result of the serum TSH response to TRH.
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CHAPTER 5 Thyroid function in patients treated with iodine-131
for thyrotoxicosis.
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Radioactive iodine has been widely used in the treatment of
thyrotoxicosis for the last twenty-five years. The initial concern
was that the irradiation might cause malignant disease, but there is
no evidence of an increased incidence of leukaemia (Pochin, 1960;
Saenger et al.f 1968) or thyroid carcinoma (McDougall et al., 1971b;
Dobyns et al., 1974). Furthermore, the radiation dose to the
ovaries is small, and the incidence of congenital abnormalities does
not seem to be increased in children of parents treated with iodine-131
for thyrotoxicosis during childhood or adolescence (Starr et al., 1969;
Hayek et al., 1970; Safa et al., 1975). Radioactive iodine is
therefore a safe form of therapy for thyrotoxicosis and is the most
common form of treatment in patients over the age of forty years in
the United Kingdom. Its main disadvantage is the increasing
incidence of hypothyroidism with the passage of time which was
originally stressed by Beling and Einhorn (1961) and confirmed by other
workers (Dunn and Chapman, 1964; Green and Wilson, 1964; Nofal et al.,
1966). The incidence is greatest in the first post-treatment year at
7-22% and continues at 2-5% thereafter (Hagen, 1968) with a cumulative
incidence of 80% fifteen years after therapy in some centres (Greig,
1973). In an attempt to reduce the complication of hypothyroidism
low dose regimens of iodine-131 were employed (Smith and Wilson, 1967;
Goolden and Fraser, 1969) which reduced the incidence of
hypothyroidism to 4-5% in the first year and to 7% after five years,
but only at the expense of a delay in controlling the symptoms of
thyrotoxicosis, necessitating further radioiodine treatment or a
prolonged course of antithyroid drugs in approximately half of the
patients. More recently, Glennon et al., (1972) showed that the low
initial incidence of hypothyroidism after low doses of iodine-131 had
increased to 48% at seventeen years after therapy, which is a similar
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incidence to that reported after larger doses of radioiodine.
In a further attempt to reduce the high post-therapy incidence of
hypothyroidism, the use of iodine-125 was proposed in the treatment of
thyrotoxicosis (Greig et al., 1969; Werner et al., 1970). The
rationale behind such a proposal was that iodine-125, unlike iodine-131,
produced low energy electrons capable of penetrating a short distance
only within the thyroid cell. Gillespie et al., (1970) calculated that
iodine-125 would irradiate the apex of the thyroid follicular cell three
times as -much as the nucleus. It was hoped that thyroid hormone
sythesis, which takes place at the apex of the cell would be affected
to a greater extent than cell division by iodine-125 irradiation, and if
so, control of the thyrotoxicosis without risk of permanent cell
destruction and hypothyroidism might have been possible. Although it
was shown that iodine-125 was effective in controlling thyrotoxicosis,
it became apparent that the incidence of hypothyroidism was similar to
that which occurred after treatment with iodine-131 (McDougall et al-,
1971a; Bremner et al., 1973) and iodine-131 remains the isotope of
choice in the treatment of hyperthyroidism. The difficulties in
reducing the incidence of hypothyroidism after radioiodine are
highlighted by Skillman et al., (1969) who found that the incidence of
hypothyroidism was similar in each of three groups of patients treated
randomly with 6, 9 or 12 mCi iodine-131. The predictability of
permanent hypothyroidism occurring in the majority of patients has
led to some workers adopting the policy of intentional ablation of
the thyroid gland with radioiodine (Wise et al., 1975), but such a
form of treatment for thyrotoxicosis has not yet been widely accepted.
At least three thousand patients are treated with radioiodine for
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thyrotoxicosis in the United Kingdom each year, but it has not proved
possible, using conventional tests of thyroid function, to predict
when or in whom hypothyroidism will develop, resulting in the follow-
up of large numbers of patients. The present study was carried out
in an attempt to define the value of the estimation of serum TSH in
predicting thyroid failure in the early months after iodine-131
therapy for thyrotoxicosis when the incidence of hypothyroidism is
greatest, and in patients treated some years previously in whom there
is a lower but significant annual incidence of thyroid failure.
PATIENTS AND METHODS
(i) Early follow-up after iodine-131 therapy for thyrotoxicosis
Seventy-two patients with a mean age of fifty-three years
(range 37-74 years) were studied, who had been treated with
iodine-131 (4-50 mCi: mode 7 mCi) for thyrotoxicosis between
August 1972 and October 1973 in the Royal Infirmary, Edinburgh.
The thyroid status of each patient was assessed clinically by
one observer (ADT) at four to eight weekly intervals after
treatment and blood withdrawn on each occasion for the
estimation of total serum T , total serum T and serum TSH.
4 3
The prospective period of follow-up was two to eighteen months.
A diagnosis of hypothyroidism was made on clinical grounds and
on the basis of a low total serum T and a raised serum TSH
4
level. Total serum T^ was measured by competitive protein-
binding analysis (normal range 60-150 nmol/1)(Seth, 1973),
total serum T^ by radioimmunoassay (normal range 1.0-3.0 nmol/1)
(Challand et al.-,1975) and serum TSH by the radioimmunoassay
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method described in Chapter 1. The upper limit of normal
for the serum TSH level for the present study was 7.4mU/l
based on an earlier calculated normal range (Irvine et al.,
1973) than the normal range of <1.8-5.7mU/l now established
for the assay.
(ii) Late follow-up after iodine-131 therapy for thyrotoxicosis
In February, 1972 the total serum and serum TSH levels were
estimated in two hundred and thirty-three euthyroid patients who
had been treated with iodine-131 for thyrotoxicosis in the
Royal Infirmary, Edinburgh, between 1954 and 1966. A group of
sixty-nine of these euthyroid patients with a raised serum TSH
level was studied again each year for three years, and a further
group of sixty-one euthyroid patients with a normal serum TSH
level was restudied at two and three years. The mean age of
each group in 1975 was sixty-three years. The number of
patients chosen for this follow-up study was arbitrarily
determined as adequate for the purpose of the present study.
Each patient was examined clinically by one observer (ADT) and
blood was withdrawn for the estimation of total serum T , total
4
serum T^ (1975 only) and serum TSH. In addition, in 1975, the
patients fasted overnight for thirteen hours prior to
venepuncture, for the estimation of serum cholesterol and
triglycerides. Hypothyroidism was diagnosed on clinical grounds
and on the basis of a low total serum T. and a raised serum TSH
4
level. For the present purpose the euthyroid state is defined
as when the patient is euthyroid clinically and when the total
serum T^ level is within the normal range, irrespective of the
level of serum TSH.
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Total serum was measured by competitive protein-binding analysis
(Seth, 1973) in 1972-1974 and by radioimmunoassay (Seth et al., 1975)
in 1975. Values obtained by these two methods showed no statistically
significant difference and the normal range for each method was 60-
150 nmol/1. Total serum T^ was measured by radioimmunoassay (normal
range 1.1-2.2 nmol/1) (Seth et al., 1976). Serum TSH was measured
as described in Chapter 1, but as in the study of the patients in the
early follow-up after iodine-131 for thyrotoxicosis, the upper limit
of normal was 7.4mu/l. Serum cholesterol and triglycerides were
measured'by "Autoanalyser" (Technicon Instruments Co.) methods
(Kessler and Lederer, 1965; Levine and Zak, 1964).
RESULTS
(i) Early follow-up after iodine-131 therapy for thyrotoxicosis
Forty-one patients were clinically euthyroid at intervals of
four to eighteen months after treatment, of whom thirty-two had
a normal serum TSH level and a normal total serum T. level.
4
In three of these thirty-two patients, each followed up for
over twelve months, a transient fall in total serum T^ to
below 60 nmol/1 was observed in the early weeks after treatment
and was associated with serum TSH levels of < 1.8, *"1.8 and
8.9mU/l. In the other nine patients remaining clinically
euthyroid, normal total serum T^ levels were associated with
serum TSH values in excess of 7.4mU/l.
Clinical hypothyroidism developed in thirty-one patients two
to eight months (mean 4.3 months) after treatment. In
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seventeen of these patients a low total serum and a high
serum TSH level preceded the clinical features of hypothyroidism
by one to four months, and in six patients both indices of
thyroid function were normal at the clinic visit one to two
months before hypothyroidism was diagnosed. A rise in the
serum TSH level preceded a fall in the total serum T^ level to
below the lower limit of the normal range in only one of the
thirty-one patients. In seven patients a low total serum
level in the presence of a normal serum TSH level was the first
indication of thyroid failure, suggesting that a low total serum
T^ level is a more sensitive index of impending hypothyroidism
than the serum TSH level.
Serial total serum T^ levels were estimated in the seven patients
in whom a low total serum T. level was the first sign of
4
developing hypothyroidism. In three of these patients the low
total serum T and normal serum TSH levels were associated with
4
total serum T^ levels of 3.5, 1.9 and 1.4 nmol/1, one to two
months after therapy with iodine-131. Pituitary TSH secretion
was presumably suppressed, albeit temporarily, by the high or
normal total serum T^ concentrations, but as the total serum
T^ levels fell in subsequent weeks, not necessarily into the
hypothyroid range, the serum TSH levels rose and clinical
hypothyroidism developed. In the remaining four patients a
low total serum T^, low total serum T^ and normal serum TSH
level were observed while the patient was clinically euthyroid
(Fig. 5.1). This phenomenon was temporary and in each case
not only was the serum TSH level elevated one month later but
o
hyperthyroidism had developed in three of the four patients.
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The fourth patient remained clinically euthyroid despite low
total serum T and T levels and a high serum TSH level for a
3 4
period of two months.
(ii) Late f°ll2w-up_after_iodine-l3l_therapy_for_thyrotoxicosis^
In February, 1972, the serum TSH level was raised in one
hundred and thirty-six (58%) of the two hundred and thirty-
three patients euthyroid after iodine-131 therapy and normal
in the remaining ninety-seven patients (42%).
The mean ±SE total serum T^, T^ and serum TSH levels in the
sixty-nine euthyroid patients with a high serum TSH level in
1972 and in those remaining euthyroid and available for study
in 1973, 1974 and 1975 are shown in Table 5.1. Only three of
these sixty-nine patients developed overt hypothyroidism in the
first year of follow-up; the serum TSH level had risen in one
patient (from 34.6 to 67.3mu/l), had fallen in the second (from
45.6 to 28.2mU/l) and had remained virtually unchanged in the
third (90.4 and 92.8mU/l). At two years sixty-four of the
sixty-six patients remaining euthyroid in 1973 were available
for study, and overt hypothyroidism had developed in a further
three patients in whom the serum TSH level remained essentially
unchanged (32.8 and 32.0; 23.5 and 26.1; 27.5 and 31.2mU/l.
At three years, fifty-eight of the sixty-one patients remaining
euthyroid in 1974 were available for study and overt hypothyroid¬
ism had developed in one further patient in whom the serum TSH
level rose from 39.0 to 64.0mU/l.
The mean +SE total serum T , T^ and serum TSH levels in the sixty-
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one patients with a normal serum TSH level in 1972 and in those
remaining with a normal serum TSH level and available for study
in 1974 and 1975 are shown in Table 5.2. None of the sixty-
one euthyroid patients with a normal serum TSH level in 1972
developed clinical hypothyroidism over the period 1972-1975.
Between 1972 and 1974 serum TSH levels became slightly raised
in three patients (9.4, 9.7 and 12.6mU/l), and between 1974
and 1975 became elevated in a further six patients (8.1, 8.3, 9.2,
10.7, 12.8 and 13.2mU/l. Five patients were lost to follow-up.
The mean total serum T^ level in the euthyroid patients with a
raised serum TSH level was significantly lower than that in the
euthyroid patients with a normal serum TSH level in 1972, 1974
and 1975 (P <0.001 on each occasion). In addition, the mean
total serum T^ level was significantly lower in the euthyroid
patients with a raised serum TSH level than in the euthyroid
patients with a normal serum TSH level (P<0.001). Mean
total serum T^ and T^ levels in the patients with normal
serum TSH levels did not differ significantly from the mean
values observed for a normal population (1.70 and 107 nmol/1
respectively).
The mean ±SE serum cholesterol and triglyceride levels in forty
euthyroid patients (33 females, 7 males) with normal serum TSH
levels and in forty euthyroid patients with high serum TSH
levels, matched for age and sex are shown in Table 5.3. There
was no significant difference either in mean serum cholesterol
or triglyceride concentrations or in their distribution
frequencies between the two groups.
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DISCUSSION
Although a raised serum TSH level is a sensitive index of thyroid
failure, the present study has shown that a low total serum level
is more indicative of impending hypothyroidism in the early months after
radi-oiodine treatment of hyperthyroidism than the serum TSH level. A
low total serum T^ level is a well recognised finding in euthyroid
patients many years after iodine-131 treatment, but is invariably
associated with high circulating levels of TSH and normal or raised
levels of "total serum T^ (Sterling et al., 1969; Sterling et al., 1971;
Bellabarba et al., 1972) . In such patients the thyroid remnant
presumably fails to meet secretory demands, pituitary TSH output rises
and increases the T^/T^ ratio in the serum and the euthyroid state is
maintained. In contrast, a low total serum T , which may be associated
with a normal serum TSH level, occurring in the early months after
iodine-131 therapy for thyrotoxicosis usually indicates the onset of
clinical hypothyroidism within weeks. Of the seven patients in whom
a low total serum T and a normal serum TSH level were found before the
4
onset of clinical hypothyroidism, a normal or raised total serum T^
concentration was present in three patients which may simply reflect
the ability of the thyroid gland, damaged by irradiation, to maintain
T^ synthesis and secretion longer than that of T , as has been shown
to occur in the thyroid gland damaged by immune mechanisms (McConnon
et al., 1971). In the other four patients the transient phenomena
of a low total serum T. and normal serum TSH level was associated
4
with a low total serum T^ level for up to two months before the onset
of clinical hypothyroidism. A possible explanation of this
phenomenon is that the metabolic effects of T^ and T^ at the thyrotroph
level persist for some time after an alteration in circulating thyroid
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hormone concentration, and the serum TSH is slow to rise despite low
levels of total serum T^ and T^. Indeed, if replacement therapy
is withdrawn from athyreotic patients serum TSH levels remain
suppressed for some days (Hershman and Edwards, 1972) and in humans
administration of thyroid hormone for seventy-two hours results in a
mark'ed decrease in pituitary TSH content (Bakke et al., 1964).
Furthermore, there is a reduced number of thyrotrophs in the pituitary
glands of patients with thyrotoxicosis (Murray and Ezrin, 1966). The
transient lack of serum TSH response to TRH which is observed despite
normal or low levels of circulating thyroid hormones after subtotal
thyroidectomy for thyrotoxicosis (Sanchez-Franco et al.,1974; Toft
II
et al., 1976b), during antithyroid drug therapy (Muhlen et al., 1975),
and following withdrawal of chronic suppressive therapy with thyroxine
(Krugman et al., 1975; Vagenakis et al. , 1975) is further evidence for
suppression of the brain-thyroid axis previously exposed to high
circulating levels of total T^ and T . Recovery of the axis, which
takes four to eight weeks in the majority of patients (see Chaper 6),
presumably requires the atrophied thyrotrophs of the anterior pituitary
gland to undergo hypertrophy and hyperplasia in order to attain normal
capacity for TSH synthesis and secretion. There is an obvious analogy
to the suppression of the hypothalamo-pituitary-adrenal axis in patients
exposed to prolonged high levels of circulating corticosteroids
(Treadwell et a., 1963; Landon et al., 1965; Livanou et al., 1967;
Jasani et al., 1967). A sluggish response of the pituitary
thyrotroph to the presence of low serum thyroid hormone levels in
patients recently treated with iodine-131 for thyrotoxicosis might
therefore be expected and explains why the measurement of total serum
T^ is a more valuable test of thyroid function than the serum TSH in
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predicting the onset of hypothyroidism in the early weeks after
radioiodine therapy.
The late follow-up study has confirmed that, in the majority of
euthyroid patients with a raised serum TSH level following iodine-131
treatment of thyrotoxicosis, the serum TSH level will remain unchanged
for long periods (Slingerland et al., 1972; Toft et al., 1973c;
Toft et al., 1974a; Tunbridge et al., 1974; Toft et al., 1975),
although hypothyroidism will continue to develop in a small proportion.
On the other hand, in no patient with a normal serum TSH level six to
eighteen years after radioiodine therapy did hypothyroidism develop
over a three year period of review, although the serum TSH level
became elevated in 5% of these patients each year. These findings
are highly relevant to the organisation of the long-term follow-up of
radioiodine treated thyrotoxic patients. In the Endocrine Clinic,
20% of patients who remain euthyroid one year after radioiodine therapy
for thyrotoxicosis have a raised serum TSH level, and from the present
study this figure increases to 58% at a mean twelve years after
treatment. If an annual rate of hypothyroidism of 2% is assumed
between one and twelve years after therapy, the calculated annual rate
of transfer of patients from a normal to a high serum TSH level is 5.5%,
which is very similar to that of 5% per year observed between 1972 and
1975 in the euthyroid patients with normal serum TSH levels after
radioiodine treatment six to eighteen years earlier. It would appear,
therefore, that serum TSH levels are of the same significance in
patients from one to eighteen years after radioiodine therapy. Serum
TSH levels should be estimated at one year after treatment, when the
early high incidence of hypothyroidism is over, and patients grouped
into (1) those with a high serum TSH level who require annual review
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and (2) those with a normal serum TSH level who require to be reviewed
at most every three years. Such a policy would reduce considerably
the follow-up of the ever-increasing numbers of patients who have been
treated with iodine-131 and who have all been reviewed at least on an
annual basis in the past either in an endocrine clinic or by means of a
computerised follow-up programme (Hedley et al., 1970; Boyle, 1974).
It is important to consider whether a raised serum TSH level
following radioiodine therapy is simply an indication for annual review
of the patients known to be at risk of developing hypothyroidism in
the future, or whether it is a sign of existing thyroid failure
albeit subclinical. Previous studies of serum TSH levels after
treatment of thyrotoxicosis by iodine-131 or partial thyroidectomy
have shown total serum T^ levels to be significantly lower in patients
with raised serum TSH levels than in those with normal serum TSH
levels (Toft et al., 1974a; Tunbridge et al., 1974; Evered et al.,
1975; Toft et al., 1975). No difference, however, was observed
in the total serum T^ levels between the two groups (Tunbridge et al.,
1974; Evered et al. , 1975). The maintenance of clinical euthyroidism
by T^ in patients with high serum TSH levels was considered to
reflect a compensatory mechanism which is probably TSH dependent.
In contrast, the present study has shown, not only total
serum T^ levels, but also total serum T^ levels in patients with high
serum TSH levels to be significantly lower than the thyroid hormone
levels of the patients with normal TSH levels after radioiodine
treatment. The falling T^ and T^ secreted by the irradiated thyroid
gland will result in a raised serum TSH level, but, unlike the
situation following subtotal thyroidectomy for thyrotoxicosis (Toft
et al., 1976b), for example, the irradiated thyroid may be unable to
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respond to a high circulating level of TSH with a compensatory increase
in thyroid hormone secretion. According to the dose of irradiation,
which will vary from follicle to follicle, there may occur delay in
mitosis followed by normal mitosis, delayed mitosis followed by cell
death in mitosis, inhibition of mitosis or cell sterilisation,
reduced cell life-span, and cell death (Doniach, 1971). It is
possible that the irradiated thyroid cell, unlike the normal cell, is
unable to hypertrophy in response to TSH or TSH receptor antibodies,
and thyroid stimulators, by inducing mitosis, may paradoxically
increase 'the rate of cell death within the gland. A raised serum TSH
level may, therefore, simply reflect the reduced output of both T^ and
T^ by the failing thyroid gland which is incapable of compensatory
increase in thyroid hormone secretion as a result of irradiation
damage.
It is not possible to determine at present whether the suboptimal
total serum T. and T levels in these patients with raised serum TSH3 4
levels after iodine-131 treatment of thyrotoxicosis indicate existing
significant hypothyroidism. It is well established that the pituitary
thyrotroph is very sensitive to minor changes in the serum levels of
total T^ and T^ (Snyder and Utiger, 1972a; Snyder and Utiger 1973),
but other organs and tissues may be less sensitive to changes in
circulating thyroid hormone levels. Indeed, no difference could be
demonstrated in serum cholesterol or triglyceride levels between the
high and normal serum TSH patients matched for age and sex, although
hypercholesterolaemia is well recognised in overt hypothyroidism
(Mason et al., 1930; Boyd and Connell, 1937; Wayne, 1960; Furman et
al., 1961). It is clear that any increase in morbidity or mortality
in the patients with raised serum TSH levels and suboptimal total T^
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and concentrations in the serum will only become apparent on long-
term follow-up.
If the patients with suboptimal thyroid hormone levels and raised
serum TSH levels are considered to be hypothyroid, it is important
to recognise the possibility of inducing thyrotoxicosis in some of the
patients if the usual thyroxine replacement dosage of between O.l and
0.2 mg daily is employed (Evered et al., 1973b). The thyroid remnant
may be autonomous due to circulating TSH receptor antibodies, and
evidence for autonomous function is provided by the observation that
the iodine uptake of the gland is uninfluenced by pharmacological doses
of exogenous TSH despite normal levels of endogenous serum TSH in
some patients previously treated with radioiodine (Irvine et al., 1973).
If clinically euthyroid patients with suboptimal total serum T^ and T^
levels and elevated serum TSH levels are to be treated with thyroxine,
it would be ideal if the replacement therapy could be adjusted such that
the levels of serum TSH in response to TRH lay within the normal range.
71
Fig. 5.1
Total serum T^, T^ (nmol/1) and serum TSH (mU/1) levels in the
four patients in whom a low total serum and level was
observed in the presence of a normal serum TSH level prior to the
development of hypothyroidism.
{ from Journal of Clinical Endocrinology and Metabolism, 39,
607-609, (1974)}
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30691205 Dayspostiodine-131therapy
SerumTSHmU/I
YearNo.ofS rumT-4Serum-3 _patients_(nmol/1) 19726988.0+1.0 19736684.0±1.0 19746184.0±1.0 1975575.0±3.01.52+0 5
SerumT.S.H.Nod velopingovert.l st _(mU/l)__hypothyroidism 25.0±2.0 22.6+1.830 21.6±2.03 26.6+2.61
Table5.1MeanserumndTSHlevels(± E)ip tientswithhigserumTSHl v li1972d patientsremaininguthyro ddvailablefostu yovertf llowingyea s( l treatedwithiodine-131f rthyrotoxicosisb tween1954nd1 66). {fromLancet,ii,576-578(1975)}
YearNo.ofS rumT-4Seru-3erumT.S.H.Nod velopingovertN .developingraised.l tt patients({HBSi/ii(mU/1)hyp rthyroidismseruT. .H.follow-up 19726113.0+4.0-4. 0.2 197458105.013.0-4.1 0.33 19754105.0+4.01.73 0. 53.9± .36 Table5.2Means rum̂,^ndTSH(± E)ip tientsw thormalse umTSHl v lsi1972a dpatients remainingeuthyroidandvailablefostu yovertf llowingeears( llreat dwith iodine-131forthyrotoxicosisbetween1954and66). {fromLancet,ii,576-578(1975)}
T.S.H. level Serum-cholesterol Serum-triglyceride
(nmol/1) (nmol/1)
Normal 6.36+0.17 1.24±0.07
High 6.53±0.19 1.41+0.12
Table 5.3 Mean serum cholesterol and triglyceride levels (+SE)
in 40 euthyroid patients with normal serum TSH levels
and in 40 euthyroid patients with high serum TSH
matched for age and sex (all treated with iodine-131
for thyrotoxicosis between 1954 and 1966)
{ from Lancet Li, 576-578 (1975)].
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CHAPTER 6 Propranolol in the treatment of thyrotoxicosis by
subtotal thyroidectomy.
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The beta-adrenergic blocking drug propranolol is effective in
alleviating many of the signs and symptoms of thyrotoxicosis such
as tachycardia, tremor, sweating, heat intolerance and anxiety
(Shanks et al., 1969) and has been shown to be of value in the
treatment of the less common accompaniments of thyrotoxicosis such
as.myopathy (Pimstone et al., 1968; Kammer and Hamilton, 1974),
steatorrhoea (Thomas et al., 1973), and periodic paralysis (Yeung and
Tse, 1974). It is used to control symptoms while patients with
suspected thyrotoxicosis are undergoing investigation, and has been
used successfully in the treatment of thyrotoxic crisis (Das and
Kreiger, 1969). It is also a useful adjunct to iodine-131 in the
treatment of thyrotoxicosis, alleviating symptoms until the radioiodine
has a therapeutic effect (Hadden et al. , 1968; Franco et al., 1970).
Propranolol does not totally reverse the signs and symptoms of hyper¬
thyroidism and has no effect upon some of the metabolic sequelae such
as the increased urinary excretion of calcium and hydroxyproline
(Georges et al., 1975) and is therefore considered to be inferior to
carbimazole in the long-term treatment of thyrotoxicosis (McLarty et
al., 1973; Mazzaferri et al., 1976).
Recently there have been reports of patients undergoing partial
thyroidectomy for thyrotoxicosis prepared solely with propranolol
(Lee et al., 1973; Michie et al., 1974). The successful treatment
at the Endocrine Clinic of a patient with thyrotoxicosis, who was
sensitive to antithyroid drugs, by subtotal thyroidectomy under cover
of propranolol and the advantages claimed for the procedure such as
reduced preparation time, more flexible timing of operation and
reduced operative blood loss, led to a change in policy with regard to
the treatment of thyrotoxicosis. Since early 1975 the majority of
7 7
patients under the age of forty-five years presenting to the
Endocrine Clinic with thyrotoxicosis have been treated by subtotal
thyroidectomy under cover of propranolol, and carbimazole has only
been used in exceptional circumstances such as in patients with asthma
or in patients unwilling to accept thyroid surgery. In view of this
change in policy in the management of patients with thyrotoxicosis it
was important not only to investigate the rate of effect of propranolol
in rendering a patient suitable for surgery, but also to establish the
surgical efficacy of the procedure, to measure thyroid function
postoperatively, and to attempt to determine an appropriate follow-up
policy for patients Lreated in this manner.
The only readily measurable objective sign of response of the thyrotoxic
patient to propranolol is the reduction in heart rate, and it was
therefore proposed to assess the heart rate response to propranolol by
continuous ECG monitoring of patients with thyrotoxicosis in an attempt
to define the minimum preoperative period of treatment.
It is apparent that there is a suppression of the brain-thyroid axis in
patients who have been exposed to high circulating levels of thyroid
hormones (Sanchez-Franco et al., 1974; Toft et al., 1974b; Krugman
II
et al., 1975; Muhlen et al., 1975; Vagenakis et al., 1975; Demeester
et al., 1976) analogous to the suppression of the brain-adrenal axis in
patients treated with pharmacological doses of steroids over a
prolonged period (Treadwell et al., 1963; Landon et al., 1965;
Jasani et al., 1967; Livanou et al., 1967). The preparation of patients
with thyrotoxicosis for subtotal thyroidectomy with propranolol allowed
an assessment of the delayed recovery of the brain-thyroid axis following
the sudden withdrawal of excess circulating thyroid hormones, by means
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of measuring the serum TSH response to TRH at various intervals after
the euthyroid state had been achieved. The period during which a
lack of response or a subnormal response of serum TSH to TRH occurs
is presumably an index of the delayed recovery of the suppressed
brain-thyroid axis.
In many clinics a diagnosis of permanent hypothyroidism is made within
three to four months of surgical treatment of thyrotoxicosis (Nofal et
al., 1966; Olsen al., 1970). Bartels (1953) found that the majority
of patierits who developed clinical hypothyroidism after subtotal
thyroidectomy for thyrotoxicosis did so within three months of surgery,
but it was possible to discontinue thyroid replacement therapy in 20%
of these patients within twelve months, indicating that in some patients
there is a period of transient hypothyroidism in the early stages after
operation. In contrast to the thyroid gland damaged by iodine-131
irradiation, the thyroid remnant after surgical treatment of
thyrotoxicosis should be capable of hypertrophy in response to
endogenous TSH, in the absence of TSH receptor antibodies. In the
present study a positive decision was made not to diagnose permanent
hypothyroidism, and if possible, not to start thyroxine replacement
therapy before six months after operation. It was hoped that such a
policy would allow the behaviour of the thyroid remnant to be monitored
in terms of thyroid function and preempt the need for thyroxine
replacement therapy in a proportion of patients.
PATIENTS AND METHODS
(i) Continuous cardiac monitoring study:
Six patients were studied (4 females, 2 males) aged twenty-six
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to sixty-three years. The diagnosis of thyrotoxicosis was made
on clinical grounds and on the basis of the total serum T and T
4 3
measured by radioimmunoassay (Seth et al., 1975; Seth et al.,
1976), and the 4 hour uptake of iodine-132 by the thyroid gland.
In addition, there was no rise in the serum TSH level following
the intravenous injection of 200 pg TRH. One patient was
studied as an out-patient and five as in-patients. The in¬
patients were allowed at least twenty-four hours to acclimatise
to the hospital environment before starting continuous monitoring.
The heart rate monitoring was carried out with miniature
tape recording equipment (Oxford Instruments) using a modified
V.5 chest electrode. The light weight and portability of these
instruments allowed the patients to undertake normal activity
during the recording periods. The C.120 'Memorex' tape
cassettes were turned over at the end of twenty-four hours
and the batteries and tape cassettes were changed every forty-
eight hours. Care was taken to ensure that tape recorder speed
variations were minimised by using the same recorder for each
patient over the taping period. The first day of monitoring
was the control day and thereafter propranolol was administered
orally in a dose of 40 mg six-hourly and monitoring continued
for a further three to four days. The completed tapes were
replayed at sixty times real-speed and were checked by two
independent observers. The signal was also processed by a
Neilson Arrhythmia Computer (Neilson, 1974) which provided
continuous heart rate measurements. These rates were stored
in a solid state memory device with two hundred and forty
individual stores. Each store therefore contained heart rate
information for a six minute period of the twenty-four hour
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tape recording. In the final analysis the number of six minute
periods during which more than six hundred sinus beats had been
detected was expressed as a percentage of the total number of
six minute periods. This was effectively the proportion of
time during which the heart rate was over one hundred beats per
minute.
(ii) Subtotal thyroidectomy study
Subtotal thyroidectomy was performed in a total of forty
patients (37 females, 3 males) of whom nine had recurrent
thyrotoxicosis and had been treated previously with
carbimazole. The mean age of the patients was thirty-four years
(range 20-63 years). The diagnosis of thyrotoxicosis was made
on clinical grounds and on the basis of the total serum T^ and
T^ levels measured by radioimmunoassay (Seth et al., 1975; Seth
et al., 1976) and the serum TSH response to 200yg TRH
intravenously. The thyroid gland was diffusely enlarged in
thirty-three patients and a multinodular goitre was present in
six patients. In the remaining patient, the thyrotoxicosis was
due to a hyperfunctioning thyroid adenoma. An electrocardiograph
was performed on each patient preoperatively and atrial
fibrillation demonstrated in three. Propranolol was given in a
dose of 40 mg six-hourly orally for a mean preoperative period of
seventeen days (range 4-60 days) and was continued throughout
the day of operation and for seven days after operation.
Patients were admitted to hospital four days prior to surgery
and were discharged on the seventh post-operative day. The
vocal cords were inspected before and after surgery by
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indirect laryngoscopy. Preoperative medication was with
diamorphine, cyclizine and atropine, and anaesthesia was
induced with an intravenous barbiturate and was maintained with
halothane, nitrous oxide and oxygen.
The operative blood loss was estimated by weighing the gauze
swabs used at operation. The weight of the thyroid remnant
was calculated by weighing a part of the removed thyroid tissue
considered to be of equal size to the thyroid remnant.
In all patients serum calcium (Gitelman, 1967), total serum T^,
total serum T levels, and serum TSH response to 200 yg
4
TRH intravenously were measured before and at one week after
surgery. Serum calcium was also estimated at forty-eight hours
postoperatively. The thyroid function tests were repeated,
in addition to clinical examination by one observer (ADT) at one,
two, three, four, six and nine months depending upon the length
of follow-up. In order to measure the acute rate of fall of
thyroid hormone levels following subtotal thyroidectomy the
total serum T^ and T^ levels were estimated daily for seven
days in fourteen patients.
RESULTS
(i) Continuous cardiac monitoring study
The effect of oral propranolol in a dose of 40 mg every six hours
for three to four days on the continously recorded heart rate of
six patients with untreated thyrotoxicosis is shown in Fig. 6.1.
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The greatest reduction in heart rate occurred during the first
day of treatment with propranolol in the five patients in whom
data was available for this period. In the sixth patient there
was a failure of the recording system on the first day of
therapy. In three of the patients there was only a small
further fall in heart rate despite continued propranolol
administration, but in the remaining patients there was a more
apparent reduction in heart rate with each successive day of
treatment. The effect of propranolol was not related to the
severity of the thyrotoxicosis. The out-patient showed as
good a response as the in-patients.
(ii) Subtotal thyroidectomy study
The clinical impression was that the operative and postoperative
course of the patients compared favourably with that of patients
prepared for subtotal thyroidectomy with carbimazole and
potassium iodide.
The mean preoperative period of treatment with propranolol was
seventeen days. The mean ±SE operative blood loss was 160 ±20 ml
and the mean ±SE thyroid remnant was estimated at 7.5±0.6 gm or
18±1% of the total gland weight. Two patients developed a
transient recurrent laryngeal nerve palsy. With the exception
of one patient in whom transient hypocalcaemia developed
requiring treatment with calciferol for a period of four weeks,
the serum calcium has remained in the normal range in all
patients throughout the period of follow-up. Two patients
have developed permanent hypothyroidism and thyrotoxicosis has
not persisted in any patient. In the three patients with
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atrial fibrillation before subtotal thyroidectomy, normal sinus
rhythm was demonstrated electrocardiographically within four
weeks of operation.
The mean ^SE total serum T^ and levels in the forty patients
before surgery were 6.9-*0.4 and 255^11 nmol/1, and on the
seventh postoperative day were 1.0±0.1 and 89.C-6.3 nmol/1
respectively. The mean ^ SE total serum T and T levels in
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fourteen of these patients before and for seven days after
thyroidectomy are shown in Fig. 6.2. Four weeks after subtotal
thyroidectomy the mean - SE total serum T^ and T^ levels were
recorded at 1.30^0.1 and 66.0-6.3 nmol/1.
There was no rise in the serum TSH levels following TRH in any
of the forty patients prior to surgery. Despite normal or low
levels of total serum T and T there was an absent or
3 4
subnormal response of serum TSH to TRH in 100% of patients at
one week, and in 65% of patients at four weeks after
thyroidectomy. The serum TSH response to TRH was considered
subnormal if the serum TSH level at twenty minutes after the
administration of TRH was less than the lower limit of response
in control subjects of 3.9rnU/l, or as occurred in three of the
patients four weeks postoperatively the basal serum TSH level
was raised, but at twenty minutes after TRH did not exceed the
upper limit of normal in control subjects of 25.3mU/l. The
serum TSH response to TRH remained absent in seven (18%) of the
patients at eight, twelve and sixteen weeks after operation.
In these seven patients who were clinically euthyroid with total
serum T^ levels well within the normal range, the total serum T^
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levels at eight weeks after operation were 1.8, 1.8, 2.1, 2.2,
2.2, 2.3, and 2.6 nmol/1 respectively. Similar levels of
total serum towards the upper limit of normal for the
assay of 2.2 nmol/1 or slightly elevated, although not in the
range usually encountered in thyrotoxicosis, were recorded at
twelve and sixteen weeks postoperatively. The pattern of
changing responsiveness of serum TSH to TRH in the total forty
patients after subtotal thyroidectomy is illustrated in Fig. 6.3
In eighteen of the patients low levels of total serum and T^
have been observed in the early weeks after surgery and have
been associated with symptoms of mild hypothyroidism. Seven of
these patients have now been followed up for at least six months,
and in five patients the levels of total serum and have
returned to the normal range in the presence of a raised serum
TSH level within six months of operation. The sequential
levels of total serum T and T. and serum TSH in these five3 4
patients with transient hypothyroidism are shown in Fig. 6.4 and
6.5. A diagnosis of permanent hypothyroidism has been made in
the two other patients at follow-up at six months after surgery
on the basis of clinical examination and persisting low levels
of total serum T_ and T and raised levels of serum TSH. The
3 4
ultimate thyroid status of the remaining eleven patients with
evidence of mild clinical hypothyroidism in the early weeks after
subtotal thyroidectomy will be decided at the review six months
after operation. In the other twenty-two patients in the study
the total serum T^ levels have remained within the normal range
and the total serum T^ levels within the normal range or slightly
elevated throughout the period of out-patient follow-up of from
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three to nine months. The serum TSH levels are either elevated
or have been transiently elevated in 50% of this group of
patients at follow-up.
DISCUSSION
The time course of action of intravenous propranolol on the heart rate
of patients with thyrotoxicosis has been well documented (Howitt and
Rowlands, 1966; Weiner et al., 1969), but the rate of response
following 'oral therapy has not been fully evaluated. Vinik et al.
(1968) demonstrated a significant fall in pulse rate in thyrotoxic
patients forty-eight hours after starting treatment with oral
propranolol, but more detailed studies do not appear to exist. By
continuously monitoring the heart rate of patients with thyrotoxicosis
it is apparent that the maximum effect of propranolol in reducing the
tachycardia of such patients is present within three to four days.
Propranolol does not, however, reduce the heart rate of patients with
thyrotoxicosis to normal levels (Howitt and Rowlands, 1966) and it is
likely that the tachycardia of hyperthyroidism is the result not only of
increased beta-adrenergic activity, but also of a direct action of thyroid
hormones on the myocardium which will be uninfluenced by beta-blockade.
The decision regarding when a patient with thyrotoxicosis, prepared with
propranolol, is suitable for surgery is arbitrary, but the policy
applied at present is to achieve a resting pulse rate of less than
ninety beats per minute. Heart rates of less than ninety per minute
have been attained using propranolol in a dose of 40 mg six-hourly
orally in all of the forty patients treated by subtotal thyroidectomy
under cover of propranolol in the present series. If propranolol is
started as soon as the decision is made to treat the patient by surgical
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means, the preoperative period with propranolol depends upon the
availability of the surgeon and the domestic arrangements of the
patient. It is unlikely that the mean preparation time with
propranolol in the present series of seventeen days could be reduced,
even although the patients were suitable for surgery some days
earlier. It is evident, however, that patients with thyrotoxicosis
can be rendered euthyroid by subtotal thyroidectomy under cover of
propranol in a shorter time than that required using established
antithyroid drugs, such as carbimazole. A further advantage of
propranolol over carbimazole in the prepartion of thyrotoxic
patients for subtotal thyroidectomy is the more flexible timing of
operation, which is to the advantage of both patient and doctor.
It is the impression that the thyrotoxic gland prepared with
propranolol is smaller and less vascular than the gland prepared with
carbimazole. The mean operative blood loss in the present study of
160 ml is small, and is less than that recorded by the same surgeon
during subtotal thyroidectomy for thyrotoxicosis in patients prepared
with carbimazole and potassium iodide (Mcintosh, 1976). It is
probable that many patients are overtreated with carbimazole with a
subsequent increase in size and vascularity of the gland under the
added stimulus of endogenous TSH.
The rates of fall of the total serum T^ and T^ levels during the
immediate postoperative period reflect in part the respective half-
lives of the thyroid hormones of twenty-four hours and six days. How¬
ever, within twenty-four hours of any surgical procedure there is a fall
in the level of total serum T due to the monodeiodination of T. by
3
. 4
an alternative pathway to form 3, 3', 5', triiodothyronine (reverse T^)
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(Burr et al., 1975), and a proportion of the fall in the total serum
following subtotal thyroidectomy may be due to this mechanism. The
decision to stop propranolol therapy on the seventh postoperative day
is based on the finding of normal levels of total serum T and T at
3 4
that time.
The acute effects of raised levels of thyroid hormones on the
adenohypophysis to prevent the release of TSH by TRH is thought to be
achieved by a protein inhibitor of TRH action (Bowers et al., 1967;
Bowers et al,,1968b) and presumably the effect of prolonged
inappropriately high levels of total serum T^ and T^ is to cause
atrophy of the TSH producing cells, or thyrotrophs, described by
Murray and Ezrin (1966) in patients with untreated thyrotoxicosis.
The study of serial levels of thyroid hormones and of the serum TSH
response to TRH in patients rendered euthyroid by subtotal
thyroidectomy under cover of propranolol has enabled the rate of
recovery of the thyrotroph to be determined. Although total serum
T^ and T^ levels were in the lower range of normal or frankly low
in the majority of patients one and four weeks after surgery, the
serum TSH response to TRH was absent in 100% of patients at one week,
and absent or subnormal in 65% of patients at four weeks after subtotal
thyroidectomy. The subnormal serum TSH response to TRH indicates
partial recovery of the thyrotroph and is intermediate between no
response of serum TSH to TRH and the augmented response characteristic
of a raised basal serum TSH level (Chapter 3). The lack of response
of serum TSH to TRH which persisted in 17% of the patients for longer
than eight weeks after surgery is not due to a delayed recovery of the
thyrotrophs, but due to a continued suppression of these cells by
levels of total serum T and/or T^ which were either in the upper part
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of the normal range or slightly elevated and reflects the
sensitivity of the anterior pituitary gland to minor changes of
circulating total and even within the normal range (Snyder and
Utiger, 1972a; Snyder and Utiger, 1973). It is evident therefore
that the thyrotroph of the anterior pituitary gland does not regain
its.capacity to respond either to normal or low levels of thyroid
hormones or to pharmacological doses of TRH for four to eight weeks
after subtotal thyroidectomy in the majority of patients. Although
the suppression of the brain-thyroid axis is not so prolonged or of
the same clinical significance as the suppression of the brain-
adrenal axis in patients previously exposed to high doses of
corticosteroids, the resultant anomalies which may occur in thyroid
function tests in the early weeks after operative treatment for
thyrotoxicosis should be appreciated.
The incidence of hypothyroidism after subtotal thyroidectomy for
thyrotoxicosis depends upon many factors among which are the size of
the thyroid remnant (Crile and McCullagh, 1951; Michie et al., 1972),
the degree of lymphocytic infiltration of the gland (Whitesell and
Black, 1949; Greene, 1950), the presence of complement fixing thyroid
antibody in the serum (Irvine et al., 1962; Buchanan et al, 1962;
Irvine and Stewart, 1967) the length of follow-up (Nofal et al., 1966)
and the progression of thyrotoxicosis to spontaneous hypothyroidism in
some patients (Baldwin, 1895; Gowan, 1895). It is apparent from the
present study that a condition of mild hypothyroidism associated with
low levels of total serum and may occur in some patients in the
early weeks after operation. However, thyroid hormone levels may
return to the normal range as a result of a raised serum TSH level
and permanent hypothyroidism should not be diagnosed with confidence
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before six months have elapsed. If, as reported by Bartels (1953)
and Nofal et al, (1966), over 50% of patients ultimately developing
hypothyroidism after thyroidectomy do so within six months of
operation, the review policy must be an important additional factor
in determining the incidence of hypothyroidism. Although there have
been many retrospective studies of the incidence of hypothyroidism
following surgical treatment of thyrotoxicosis (Green and Wilson,
1964; Roy et al., 1967; Beahrs and Sakulsky, 1968; McNeill and
Thomson, 1968; Olsen et al., 1970; Evered et al., 1975) with
figures of between 6% at ten years and 43% at five years of follow-up,
there is little information available about the stage at which the
diagnosis of permanent hypothyroidism was made postoperatively.
It is possible, therefore, that some of the variation from centre to
centre in the incidence of hypothyroidism may be accounted for by the
review policy of the clinic.
The efficacy of subtotal thyroidectomy for thyrotoxicosis under cover
of propranolol has been established. Consideration should therefore be
given to the preoperative preparation of patients with propranolol in
whom there is an indication for thyroidectomy and in whom there is no
history of asthma or cardiac failure. Diabetes mellitus may be a
relative contradiction since propranolol has been shown to directly
cause hypoglycaemia (Kotler et al., 1966) and may mask the signs and
symptoms of hypoglycaemia which are mediated by beta-adrenergic
receptors. It should also be stressed, however, that the short half-
life of propranolol of 3.2 hours (Shand et al., 1970) makes the
administration of the drug on the morning of operation, and every six
hours postoperatively, mandatory.
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The present study has also defined the patterns of total serum T , T
3 4
and TSH which occur in the early months after surgery. Although the
period of follow-up has been short, it is unlikely that the incidence
of recurrent thyrotoxicosis or permanent hypothyroidism will be
significantly different in the long-term than in patients prepared for
surgery with carbimazole and potassium iodide.
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Fig. 6.1
The effect of oral propranolol 40 mg six-hourly on the continuously
monitored heart rate of six patients with untreated thyrotoxicosis.
{from Clinical Endocrinology, 5^ 195-198 (1976)}
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Fig. 6.2
Mean ±SE total serum T and T levels in fourteen patients before and3 4
for seven days after subtotal thyroidectomy for thyrotoxicosis under
cover of propranolol.
{from Journal of Clinical Endocrinology and Metabolism (1976) (In press)}
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Fig. 6.3
The percentage of patients with absent or subnormal response of serum
TSH to 200 yg TRH i.v. at one, four, eight, twelve and sixteen weeks
after subtotal thyroidectomy for thyrotoxicosis under cover of
propranolol.
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Fig. 6.4
Total serum T . T„ and TSH levels before and for six months after
3 4
subtotal thyroidectomy for thyrotoxicosis under cover of propranolol in
three patients in whom transient clinical hypothyroidism was observed.
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Fig. 6.5
Total serum T_, T, and TSH levels before and for six months after
3 4
subtotal thyroidectomy for thyrotoxicosis under cover of propranolol in
a further two patients in whom transient clinical hypothyroidism was
observed.
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AN ASSESSMENT OF PLASMA TSH
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SUMMARY
A plasma TSH estimation and a TSH stimulation test were performed on each of
100 consecutive patients seen at a thyroid clinic in whom it was necessary to
exclude a diagnosis of hypothyroidism. None of the patients had received replace¬
ment therapy. The normal response to 10 i.u. bovine TSH administered intra¬
muscularly on three consecutive days was shown to be an absolute increment in
the 4 hr uptake of 132I by the thyroid gland of at least 13%. The mean plasma
TSH in twenty-five untreated euthyroid patients, who had neither goitres nor
thyroid antibodies, whose TSH stimulation tests were normal and in whom there
was no evidence of hypopituitarism, was 3-8 ^U/ml + 3-6 (2 S.D.). All forty-nine
patients with primary hypothyroidism had plasma TSH levels in excess of 25
/(U/ml. In eighty-nine of the 100 patients, the radioimmunoassay of plasma TSH
and the TSH stimulation test gave similar information about the reserve of thyroid
function and in five euthyroid patients the plasma TSH was >7-4 /tU/ml while the
TSH stimulation test was normal. The remaining six subjects (including one
patient with hypopituitarism and three who had been treated with radioiodine for
thyrotoxicosis) were euthyroid with an abnormal TSH stimulation test and a
plasma TSH of <7-4 p\J ml.
For clinical purposes a plasma TSH of <7-4 yttU/ml indicates a normal reserve
of thyroid function, a plasma TSH between 7'4 and 25 /tU/ml is equivocal, and a
plasma TSH >25 /tU/ml indicates an impaired or absent reserve of thyroid function
with or without hypothyroidism. It is concluded that a single plasma TSH
estimation should replace the time-consuming TSH stimulation test in the
assessment of thyroid reserve.
Correspondence: Dr W. J. Irvine, Department of Endocrinology, The Royal Infirmary, Edinburgh
EH3 9YW.
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INTRODUCTION
The TSH stimulation test demonstrates the reserve capacity of the thyroid gland and is
most widely used in the diagnosis of primary hypothyroidism. It has the disadvantage of
being time-consuming for the patient and supplying to the thyroid gland a pharmacological
stimulus in terms of normal pituitary output of TSH (Bakke et al., 1962). The test procedure
varies (Hall et al., 1969; McHardy-Young et al., 1972) and there appears to be little agree¬
ment as to what is the definition of a normal response.
The purpose of the present study was to correlate the plasma TSH measured by radio¬
immunoassay with the result of the TSH stimulation test.
PATIENTS
The subjects were 100 consecutive patients seen at the Endocrine Clinic, Royal Infirmary,
Edinburgh, in whom it was necessary to confirm or exclude a diagnosis of primary hypo¬
thyroidism. The final diagnosis was made from clinical examination and from estimations
of serum protein-bound iodine and total serum thyroxine (Toft et al., 1973), augmented
when necessary by serum cholesterol, electrocardiograph and ankle reflex time, as well as
the patient's response to replacement therapy with thyroxine. Patients on thyroid replace¬
ment therapy were excluded.
There were fifty-one euthyroid patients. Thirty-three were referred by their general
practitioners with suspected hypothyroidism and five of these had goitre. The other eighteen
patients had previously attended the Endocrine Clinic; eight had received 131I and two had
undergone surgery for thyrotoxicosis, four had idiopathic Addison's disease, two had
hypopituitarism and two had pernicious anaemia with thyroid antibodies in the serum.
There were forty-nine hypothyroid patients, of whom ten had spontaneous hypothyroidism
and had been referred by their general practitioners; thirty-six had been previously treated
with 131I and three had undergone subtotal thyroidectomy for thyrotoxicosis.
The present study was done following that reported in the adjoining paper (Toft et al.,
1973) involving different patients.
METHODS
TSH stimulation test. After measurement of the 4 hr uptake of 132I by the thyroid 10 i.u.
bovine TSH (thytropar) was administered intramuscularly at 16.00 hours on three consecu¬
tive days. The uptake measurement was then repeated on the day following the last injection.
The potency of each batch of bovine TSH was verified.
Plasma TSH. The radioimmunoassay of plasma TSH was carried out using a modification
of the double antibody method of Odell et al. (1967) as described in the adjoining paper
(Toft et al., 1973).
Thyroid antibody studies. Antibodies to thyroid cytoplasm were detected by the indirect
immunofluorescence technique using sections of human thyroid tissue and by complement
fixation using a saline extract of human thyroid.
RESULTS
Among the forty-nine patients with untreated hypothyroidism the largest increase in the
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thyroid gland uptake of 132I at 4 hr, relative to the dose of isotope given to the patient, was
8% following TSH stimulation (e.g. a 4 hr thyroid gland uptake of 132I increasing from
7% to 15%). Therefore the increment in the thyroid gland uptake in normal subjects in
response to exogenous TSH must be greater than 8%.
Estimations of plasma TSH in the forty-nine patients with primary hypothyroidism
ranged from 26 to 537 /rU/ml. The mean plasma TSH in the twenty-five euthyroid patients
without goitre, without thyroid antibodies in the serum, who had not previously undergone
thyroid surgery or therapy with 131I, who had no evidence of hypopituitarism and whose
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Fig. 1. Plasma TSH levels (/iU/ml) correlated with diagnosis and results of TSH stimulation
tests in 100 consecutive patients investigated for suspected hypothyroidism. The horizontal
line at 7-4 //U/ml represents the mean (3-8) -F2 S.D. of the plasma TSH levels in twenty-five
euthyroid patients who had no goitres, who had not previously been treated by 131I or thyroid
surgery, whose serum was negative for thyroid antibodies, who had no evidence of hypo¬
pituitarism and who had normal TSH stimulation tests (an absolute increment of > 13% in the
4 hr thyroid gland uptake of 132I following 10 i.u. bovine TSH on each of 3 days). O, Post
1311; □, post thyroidectomy; v, spontaneous primary hypothyroidism; A, untreated euthyroid;
+ , hypopituitary without thyroid antibodies in the serum. Solid symbols indicate that
thyroid cytoplasmic antibodies were present in the serum.
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4 hr thyroid gland uptake of 132I increased by at least 8% with exogenous TSH was 3-8
^U/ml+ 3-6 (2 S.D.). On this basis the clinic normal range for plasma TSH in patients with
no evidence of thyroid dysfunction is estimated to be between 0 and 7-4 /uU/ml (mean + 2
S.D.).
Combining all the euthyroid patients in the present series, an attempt was made to define
more precisely the limits of normal in the TSH stimulation test by determining the figure
which correlated best with the plasma TSH levels, i.e. that as few patients as possible were
defined as having a normal plasma TSH and an abnormal TSH stimulation test. On this
basis, the normal absolute increase in the thyroid gland uptake of 132I at 4 hr following
10 i.u. bovine TSH i.m. on each of three consecutive days, was 13% or more.
In the five euthyroid patients with plasma TSH levels within the range encountered in
primary hypothyroidism (i.e. >25 ^U/ml), the TSH stimulation test was abnormal in four.
In the six euthyroid patients with plasma TSH values between 7-4 and 25 /rU/ml the TSH
stimulation test was normal in four and abnormal in two (14-18% and 18-15%, respec¬
tively). Plasma TSH measurements in this range were therefore regarded as equivocal. Three
of the five euthyroid patients with plasma TSH levels >7-4 pU/ml and a normal TSH
stimulation test had thyroid antibodies in the serum; a further patient had had 131I therapy,
leaving only one patient with a slightly elevated plasma TSH of 8-8 /.iU/ml for which no
explanation could be offered. There was no correlation between the titre of thyroid anti¬
bodies and the plasma TSH levels in the euthyroid patients with a normal TSH stimulation
test. Of the six patients with an abnormal TSH stimulation test and normal plasma TSH
levels, three had received therapy with 131I (15-19%; 24-30%; 14-16%) and one was
suffering from hypopituitarism (7-18%), leaving only two patients who had not received
previous therapy directed at the thyroid gland (13-21%; 19-27%).
DISCUSSION
Plasma TSH levels were in excess of 25 juU/ml in all of the forty-nine patients with primary
hypothyroidism included in the present paper as well as in an additional twelve patients
with primary hypothyroidism reported in the adjoining paper (Toft et al., 1973), making a
total of sixty-one patients. In contrast, the plasma TSH levels in the twenty-five patients
with no definite history of thyroid disease or without any demonstrable abnormality of
the thyroid gland was 0-7-4 juU/ml (95% confidence limits). This indicates that for
clinical purposes a markedly elevated plasma TSH level is diagnostically important in
relation to primary hypothyroidism. In keeping with this is the observation that four of the
five euthyroid patients with a plasma TSH >25 ^U/ml (45-93 ^U/ml) had impaired reserve
of thyroid function as evidenced by a low increment in the uptake of 132I by the thyroid
gland at 4 hr following prolonged stimulation by a large dose of exogenous TSH. Therefore
a high plasma TSH level, although always present in primary hypothyroidism, may also
indicate a preclinical condition of impaired reserve of thyroid function without any signi¬
ficant fall in the secretion of thyroxine. A plasma TSH level of between 7-4 and 25-0 /<U/ml
should be regarded as equivocal; four of six patients with levels within this range having
a normal TSH stimulation test. However, the use of a large dose of exogenous TSH as
employed in the present study in the stimulation test might have masked a minor degree of
impaired reserve of thyroid function.
Of the six euthyroid patients with an abnormal TSH stimulation test but with normal
plasma TSH levels, three had previously had thyrotoxicosis and had been treated with 131I
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and one patient had hypopituitarism. It is conceivable that after therapy with 131I thyrotoxic
patients may go through a phase in which they are euthyroid by virtue of the autonomous
function of the remaining thyroid tissue and are therefore unable to respond to exogenous
TSH stimulation. Presumably this is particularly likely to occur in patients with diffuse
goitre. Thus out of the total 100 patients, in eighty-nine the radioimmunoassay of plasma
TSH and the TSH stimulation test gave similar information about the reserve of thyroid
function. Taking into consideration the arguments just discussed, there were only two
patients in whom false negative results were apparently obtained in euthyroid subjects who
had an abnormal TSH stimulation test but a normal plasma TSH level.
Previous studies on plasma TSH levels in hypothyroidism and in healthy subjects have
not correlated the findings with TSH stimulation tests, nor have they defined a clinical
euthyroid range for plasma TSH in patients with a normal reserve of thyroid function.
Hershman & Pittman (1971) found the plasma TSH levels to range from 24 to 800 /(U/ml
in sixty-one patients with untreated primary hypothyroidism and Mayberry et at. (1971) in
a series of 156 patients with primary hypothyroidism reported serum TSH measurements
in 154 to be >15 /(U/ml. Ormston et at. (1971) described five patients with 'definite' hypo¬
thyroidism with a serum TSH of 3-4—14-8 /(U/ml but all these five patients had serum PBI
values of >4-0 /tg%. The seventeen patients with adequate evidence of hypothyroidism in
the latter series all had serum TSH levels > 19-0 /(U/ml. The serum or plasma TSH levels
in healthy subjects have been variously reported in recent years as being between < 1 -0-19 0
/(U/ml as reviewed by Hall (1972), but in the majority of reports the normal range is
<10 /(U/ml.
Although we have been able to define a normal response by the thyroid to exogenous
TSH more precisely than hitherto, this form of test is time-consuming for the patients
compared to venepuncture for measurement of the plasma TSH level. The evidence in this
paper indicates that the TSH stimulation test is no longer necessary if there is access to a
reliable radioimmunoassay for plasma or serum TSH on a routine basis.
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LEVELS IN PRIMARY HYPOTHYROIDISM:
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(.Received 9 May 1973)
It has been established in animals that anterior pituitary hormones control their
own secretion by regulating at a hypothalamic level the release of their hypothalamic
factors (Motta, Fraschini & Martini, 1969). If a negative 'short-feedback' of thyroid-
stimulating hormone (TSH) on the hypothalamus exists in man, the high plasma TSH
levels of untreated primary hypothyroidism should fall markedly after the administra¬
tion of bovine TSH which shares the biological, but not the immunological, proper¬
ties of human TSH. This report describes the effects of bovine TSH on human
plasma TSH (H-TSH) levels in patients with primary hypothyroidism.
Twenty-seven patients with untreated primary hypothyroidism were studied,
of whom 20 had been treated with 131I and four by subtotal thyroidectomy for
thyrotoxicosis. The remaining three patients had spontaneous primary hypothy¬
roidism . The diagnosis of primary hypothyroidism was made on clinical grounds and
on the basis of a low serum protein-bound iodine (< 3-8 /ig/100 ml), a low total
serum thyroxine (< 4-5 /ig/100 ml) and a high H-TSH ( > 25 /iu./ml) measured by
radioimmunoassay using a double antibody method (Irvine, Toft, Hunter & Kirk-
ham, 1973). There was no significant increase in the 4-h 132I uptake by the thyroid
gland after the intramuscular administration of 10 i.u. bovine TSH ('Thytropar') on
each of 3 successive days in any patient.
In three patients H-TSH was estimated before and 7, 15, 25, 30 (two patients only),
45, 60, 90 (two patients only), 120 and 180 min after the intramuscular injection of
10 i.u. bovine TSH (Fig. 1). None of the three patients showed a fall in the level of
H-TSH after exogenous bovine TSH injection.
A TSH stimulation test employing 10 i.u. bovine TSH intramuscularly at 16.00 h
daily for 3 days was carried out in the remaining 24 patients. Human plasma TSH
was estimated before the first and 18 h after the last injection of bovine TSH. The
mean H-TSH level + s.e.m. before the TSH stimulation test was 87-3 +11-2 yu./ml
(range 27-2-210-3 /iu./ml) and 84-7 + 11-4 yu./ml (range 35-5-221-3 /i.u./ml) after the
TSH stimulation test. The H-TSH level after exogenous bovine TSH injection fell
in 13 patients, the maximum percentage decrease being 33% (69-5 —> 44-5 y-u./ml),
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Fig. 1. Human plasma thyroid-stimulating hormone (TSH) levels in three patients with
untreated primary hypothyroidism in response to 10 i.u. bovine TSH intramuscularly;
arrow indicates time of injection.
but rose in the other 11 patients, the maximum percentage increase being 30-5%
(27-2 -> 35-5 /tu./ml).
We have been unable to show a fall in the high H-TSH levels in patients with
untreated primary hypothyroidism despite the presence of high bovine plasma TSH
levels lasting 24 h, achieved in such patients after the administration of exogenous
bovine TSH (Hershman & Edwards, 1972). There is, therefore, no evidence for the
existence of a negative 'short-feedback' of TSH on the hypothalamus in man.
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_ 69 euthyroid patients who had raised
plasma - thyroid - stimulating - hormone
(t.s.h.) levels (>7-4 pu. per ml.) in February, 1972,
after 131I therapy for thyrotoxicosis between 1954-66
were reassessed fifteen months later. The initial
mean plasma-t.s.h. level ±s.e. in the 66 patients who
remained euthyroid (25 0 + 2 0 pu. per ml.) was
unchanged (22-6+1-8 pu. per ml.) at the end of the
study. Overt hypothyroidism developed in only 3
patients with initial plasma-t.s.h. levels of 34-6, 45-6,
and 90-4 pu. per ml. At follow-up these patients had
plasma-t.s.h. levels of 67-3, 28-2, and 92-8 pu. per
ml., respectively. Since raised plasma-t.s.h. concen¬
tration occurring after radioiodine treatment of
thyrotoxicosis does not alter for a considerable period,
it cannot be used as an indication of impending overt
hypothyroidism.
Introduction
A raised plasma-thyroid-stimulating-hormone
(t.s.h.) level is now regarded as the most sensitive
index of thyroid failure. Evered and Hall1 judged
euthyroid people with raised plasma-t.s.h. but no
symptoms of thyroid dysfunction to have preclinical
hypothyroidism. The natural history of such a con¬
dition is not known. The present prospective study
was designed to observe the clinical and biochemical
progress of a large group of euthyroid patients with
raised plasma-t.s.h. levels induced by 131I treatment
of thyrotoxicosis.
Patients and Methods
69 patients (52 females and 17 males), aged thirty-
eight to eighty, who had been treated with '"I for thyro¬
toxicosis between 1954 and 1966 in the Royal Infirmary,
Edinburgh, were studied. In February, 1972, and May,
1973, the thyroid status of each patient was assessed
clinically and blood was withdrawn to estimate serum-
protein-bound-iodine (p.b.i.), total serum-thyroxine (T4),
and plasma-t.s.h. Serum-p.b.i. was estimated by a
modification of the Technicon N-56 method,2 serum-T4
by a modification of the competitive-protein-binding
method of Maclagan and Howorth,3-4 and plasma-t.s.h.
by a sensitive double-antibody radioimmunoassay.5
Results
The mean ( + S.E.) serum-P.B.i., serum-T4, and
plasma-T.s.H. for the 66 patients who remained
euthyroid are shown in the accompanying table.
SERUM-P.B.I., SERUM-T4, AND PLASMA-T.S.H. IN FEBRUARY, 1972,
AND MAY, 1973, IN 66 PATIENTS WHO REMAINED EUTHYROID
Serum-P.B.i. Serum-T4 Plasma-T.s.H.
(M-g- per (pig. per (piU. per
Time 100 ml.) 100 ml.) ml.)
(mean±s.E.) (mean rts.E.) (mean ±S.E.)
February, 1972 5-7 ±0-2 6-8 ±0 1 25 0±2 0
May, 1973 5-6 ±0-2 6 5±0 1 22-6 4-1-8
There was no apparent change in any measurement
of thyroid function at the end of the fifteen-month
period. The ranges of plasma-T.s.H. levels in
February, 1972, and in May, 1973, were 8-7-60 /xu.
per ml. and 7 5-50 /xu. per ml., respectively. The
greatest relative increase in plasma-T.s.H. over fifteen
months in any patient remaining euthyroid was from
10-2 to 22-3 /xu. per ml., and the greatest relative
fall was from 26-4 to 11-3 /xu. per ml. Overt hypo¬
thyroidism had developed in 3 of the initial 69
patients after fifteen months. The plasma-T.s.H. level
had risen in 1 (from 34-6 to 67-3 /xu. per ml.), had
fallen in the second (from 45-6 to 28-2 /xu. per ml.),
and had remained unchanged in the third (i.e., 90-4
and 92-8 /xu. per ml.).
Discussion
In many centres radioiodine is the treatment of
choice for thyrotoxicosis in patients over forty. The
incidence of subsequent hypothyroidism is highest
3
during the first post-treatment year (7-22%) and
continues at 2-4",, per year thereafter.6 The ability
to forecast not only which patients were at risk of
developing hypothyroidism but also when it would
develop would be very valuable. Conventional tests
of thyroid function cannot identify such patients, and
this has resulted in the follow-up of large numbers
of patients. Indeed, the interpretation of thyroid-
function tests after 1311 therapy for thyrotoxicosis may
be difficult. The t.s.h. stimulation test, which indi¬
cates the reserve capacity of the thyroid gland, is
often abnormal,78 and an abnormal result may be
associated with a normal plasma-T.s.H. level.5
Patients may be clinically euthyroid, with normal
serum-triiodothyronine but low serum-T4 concen¬
trations.9"11 Furthermore, Slingerland et al.12 have
found high serum-T.s.H. levels in about 50% of
euthyroid patients treated with radioiodine for thyro¬
toxicosis five to twenty-two years earlier, and they
described 7 patients who had remained euthyroid
despite raised serum-T.s.H. levels for nineteen to
forty-one months.
In the present study, not only did 66 of 69 patients
(94%) with high plasma-T.s.H. levels remain
euthyroid over fifteen months, but the plasma-T.s.H.
levels were essentially unchanged. It was not possible
to predict from the plasma-T.s.H. concentration which
patients would later have overt hypothyroidism.
Raised plasma-T.s.H. levels, which result from a
resetting of the brain-thyroid axis, are relatively
stable, at least after radioiodine therapy, and are not
a sign of the imminent development of frank hypo¬
thyroidism. Serial measurements of plasma-T.s.H.
are therefore unlikely to be of value in the long-term
follow-up of patients treated with 131I for thyro¬
toxicosis, unless raised plasma-T.s.H. itself can be
shown to be detrimental.
Requests for reprints should be addressed to W. J. I.,
Department of Endocrinology, Royal Infirmary, Edinburgh
EH3 9yw.
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PLASMA THYROTROPHIN AND SERUM
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o Clinical examination and measure¬
ments of plasma-thyrotrophin (t.s.ii.)
and total serum-thyroxine (T4) were made at 1-2-
monthly intervals in seventy-two patients treated
with iodine-131 for thyrotoxicosis. The period of
prospective follow-up was 2-18 months. Forty-one
patients were euthyroid with normal serum-T4 levels
(4.5-11.5 p.g. per 100 ml.), of whom thirty-two had
a normal and nine a high plasma-t.s.h. level (>7.4
yuu per ml.). Hypothyroidism developed in thirty-one
patients (43%). In seventeen, a low serum-T4 and
a high plasma-t.s.h. preceded the symptoms of hy¬
pothyroidism by 1—4 months, but in seven patients a
low serum-T4 in the presence of a normal plasma-
t.s.h. level was the first indication of developing
hypothyroidism. In six patients both indices of thy¬
roid function were normal at the clinic visit 1-2
months before hypothyroidism was diagnosed, and
in only one patient did the plasma-t.s.h. rise precede
the fall in serum-T4. It is concluded that the serum-
T4 may be a more sensitive index of thyroid failure
than the plasma-t.s.h. in the early months after
iodine-131 treatment of thyrotoxicosis.
Introduction
Although a raised plasma-r.s.h. level is a sensi¬
tive index of thyroid failure, Toft et a!.1 demon¬
strated that high circulating levels of t.s.h. may per¬
sist for many months in euthyroid patients treated
7-19 years earlier with iodine-131 for thyrotoxicosis.
The present study was designed to determine
whether the routine measurement of plasma-t.s.h.
is of value in predicting the onset of hypothyroidism
in the early months after iodine-131 treatment of
thyrotoxicosis when the incidence of hypothyroidism
is greatest.2
Patients and Methods
We studied seventy-two patients (sixty-two females
and ten males), aged 37-74 years, who had been treated
with iodine-131 (4-50 mCi, mode 7 mCi) for thyrotoxi¬
cosis between August, 1972, and October, 1973, in the
Royal Infirmary, Edinburgh. The thyroid status of each
patient was assessed clinically by one observer (A. 1). T.),
and blood was withdrawn for the estimation of serum-T4
and plasma-t.s.h. at 1-2-monthly intervals after treat¬
ment. Hypothyroidism was diagnosed clinically and in the
presence of a serum-T4 of <4.5 fig. per 100 ml. and a
plasma-t.s.h. of > 7.4 fiv per ml. The prospective period of
follow-up was 2-18 months. Serum-T4 was estimated by
a modification of the competitive-protein-binding method
of Maclagan and Howorth,3,5 and plasma-t.s.h. by a
sensitive double-antibody radioimmunoassay.5
Results
Three patterns of plasma-t.s.h. and serum-T4
levels were observed after iodine-131 treatment of
thyrotoxicosis.
1. Thirty-two patients were clinically euthyroid at
intervals varying from 4 to 18 months after therapy,
with normal plasma-t.s.h. and normal serum-T4
levels. Three of this group, followed up for over
12 months, had a transient fall in serum-T4 to below
4.5 fig. per 100 ml. in the early weeks after treat¬
ment, which was associated with plasma-t.s.h. values
of 1.7, <1.5, and 8.9 fiu per ml.
2. Nine clinically euthyroid patients were found
to have normal serum-T4 levels associated with
plasma-t.s.h. levels in excess of 7.4 fiu per ml. 6-18
months after treatment.
3. Clinical hypothyroidism developed in thirty-one
patients 2-8 months (mean 4.3 months) after iodine-
3
131 treatment. Tn seventeen of these patients a low
serum-T4 and a high plasma-T.s.H. level preceded
the clinical features of hypothyroidism hy 1—1
months, and in six patients both indices of thyroid
function were normal at the clinic visit 1-2 months
before hypothyroidism was diagnosed. In a further
seven patients a low serum-T4 level in the presence
of a normal plasma-T.s.H. level was the first indi¬
cation of developing hypothyroidism. A rise in
plasma-T.s.H. preceded a fall in serum-T4 in only
one out of thirty-one patients developing clinical
hypothyroidism.
Discussion
The treatment of thyrotoxicosis with iodine-131
may either make patients euthyroid with normal or
high plasma-T.s.H. levels or induce hypothyroidism.
The incidence of hypothyroidism after radioiodine
is highest during the first post-treatment year and
continues at a lower rate thereafter.2 The high inci¬
dence of hypothyroidism in the present study may
reflect the high dose of isotope given in this centre,
especially to patients with the cardiac complications
of thyrotoxicosis. An increased plasma-T.s.H. level
in euthyroid patients after iodine-131 treatment of
thyrotoxicosis may persist for many months,1'6 and
Toft et al.1 felt that the routine measurement of
plasma-T.s.H. was not of value in predicting the oc¬
currence of late hypothyroidism in a group of pa¬
tients treated with iodine-131, 7-19 years previously.
However, in patients in whom hypothyroidism de¬
veloped within a few months of treatment, an in¬
creased plasma-T.s.H. level might be expected to
predict impending hypothyroidism. In 55% of patients
in whom hypothyroidism developed, both a low
serum-T4 and a high plasma-T.s.H. level were
found when the patient was clinically euthyroid
1-4 months earlier. Although the serum-triiodothy-
ronine (T3) levels were not estimated, these patients
presumably fall into the category of patients main¬
tained temporarily euthyroid by normal or high
levels of circulating T3.7-9 The occurrence of low
serum-T4 levels and normal plasma-T.s.H. levels be¬
fore the onset of hypothyroidism and in the absence
of thyroxine-binding-globulin abnormalities demands
that serum-T3 levels are appropriately raised in
such patients. In patients in whom hypothyroidism
develops in the early months after iodine-131 treat-
4
ment of thyrotoxicosis, thyroxine synthesis probably
declines more rapidly than T3 synthesis, and T3 is
able to maintain euthyroidism for a period. Further¬
more the altered T3/T4 ratio is such in some pa¬
tients that the serum-T4 may be low with a normal
plasma-T.s.H. Such a state is also temporary and
eventually the secretion of T3 by the damaged gland
falls, the plasma-T.s.H. level rises, and the symptoms
of hypothyroidism develop. With the exception of
10% of patients who remain euthyroid and in whom
a transient fall in serum-T4 was observed in the first
weeks after iodine-131 therapy, this study has shown
a low serum-T4 level to be a more sensitive index of
impending hypothyroidism than the plasma-T.s.H.
Requests for reprints should be addressed to W. J. I.,
Department of Endocrinology, Royal Infirmary, Edinburgh
EH3 9YW.
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Plasma TSH and Serum T-4 Levels in Long-term
Follow-up of Patients Treated with 131I for Thyrotoxicosis
A. D. TOFT, W. J. IRVINE, W. M. HUNTER, J. SETH
Summary
In February 1972 58% of patients euthyroid after iodine-
131 therapy given for thyrotoxicosis between 1954 and
1966 had a high plasma TSH (>7-4 nU/ml) and 42% a
normal plasma TSH level. A group of 69 of the euthyroid
patients with high plasma TSH levels (25-0±2-0 nU/ml)
in 1972 were re-examined 15 and 24 months later. The
mean plasma TSH in the 66 patients remaining euthyroid
at 15 months was 22-6 ±1-8 nU/ml, while three patients
had become hypothyroid. At 24 months 64 of the
patients were still available for study, of whom 61 re¬
mained euthyroid with a mean plasma TSH of 21-6 ±2 0
fj.U/ml, and a further three had become hypothyroid.
All of a group of 61 of the euthyroid patients with nor¬
mal plasma TSH levels (40±0-2 nU/ml) in 1972 remained
euthyroid at 24 months with a mean plasma TSH of
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4-1 ±0 3 [iU/ml, though the plasma TSH level had become
slightly raised in three.
The mean serum T-4 level in the euthyroid patients
with a high plasma TSH was significantly lower, though
still in the normal range, than that in the euthyroid
patients with a normal plasma TSH both in 1972 and in
1974.
Since no patient with a normal plasma TSH level after
iodine-131 treatment six to 18 years earlier for thyro¬
toxicosis developed hypothyroidism over a two-year
period, the follow-up of such patients need not be so
rigorous as that of similarly treated euthyroid patients
with raised plasma TSH levels in whom hypothyroidism
developed at the rate of 5% per year.
Introduction
The incidence of hypothyroidism after 1S1I treatment of thyro¬
toxicosis is greatest in the first year (7-22%) and continues at
2-4% a year (Hagen, 1968). Toft et al. (1974) found a low serum
thyroxine (T-4) level to be a sensitive index of developing hypo¬
thyroidism in the early months after radioiodine therapy but it
has not yet proved possible, using conventional tests of thyroid
function, to predict when or in whom hypothyroidism will occur
in later years. This results in the follow-up of large numbers of
patients. A high plasma thyrotrophin (TSH) level is considered
to be a good index of thyroid failure but is not uncommon after
131I treatment of thyrotoxicosis and may persist in euthyroid
patients for many months (Slingerland et al., 1972; Toft et al.,
1973). The present paper reports the clinical and biochemical
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progress over two years of a group of euthyroid patients with
high plasma TSH levels and of a group of euthyroid patients
with normal plasma TSH levels who were treated with 131I for
thyrotoxicosis between 1954 and 1966. On the basis of the plasma
TSH level a rational follow-up policy is suggested for the ever-
increasing number of patients who are being treated with
radioiodine.
TABLE II—Mean Serum T-4 and Plasma TSH Levels (±S.E.) in 61 Patients
with Low Plasma TSH Levels in 1972 and 1974. All were Treated with ,3I1
for Thyrotoxicosis between 1954 and 1966
Serum T-4 Plasma TSH
(Hg/100ml) (nU/ml)
February 1972 8-7+0-3 4-0+0-2
February 1974 8-1 ±0-2 41 ±0-3
Patients and Methods
In February 1972 the plasma TSH and serum T-4 were
estimated in 233 euthyroid patients who had been treated with
131I for thyrotoxicosis in the endocrine clinic of the Royal
Infirmary, Edinburgh, between 1954 and 1966. A group of 69
of these euthyroid patients with raised plasma TSH levels were
studied again 15 and 24 months later, and a further group of 61
euthyroid patients with normal plasma TSH levels were studied
again at 24 months. Each patient was examined clinically by one
observer (A.D.T.) and blood was withdrawn for the estimation
of serum T-4 and plasma TSH. A diagnosis of hypothyroidism
was made on clinical grounds and on the basis of a low serum
T-4 (<4-5 fig/100 ml) and a high plasma TSH (>7-4 (iU/ml)
Serum T-4 was measured by competitive protein-binding
analysis (Seth, 1973) and plasma TSH by a sensitive double-
antibody radioimmunoassay (Irvine el al., 1973).
Results
The plasma TSH level was raised in 136 (58%) of the 233
patients euthyroid after 131I therapy for thyrotoxicosis between
1954 and 1966 and normal in 97 (42%) when estimated in
February 1972.
The mean (±S.E.) serum T-4 and plasma TSH levels in the
69 euthyroid patients with high plasma TSH levels in 1972 and
in those remaining euthyroid in 1973 and 1974, 15 and 24 months
later, are shown in table I, Only three of the 69 patients de¬
veloped hypothyroidism over the 15-month period; the plasma
TSH had risen in one (from 34-6 to 67-3 fzU/ml), had fallen in
the second (from 45-6 to 28-2 nil/ml), and had remained virtu¬
ally unchanged in the third (90-4 and 92-8 u.U/ml). At 24 months
64 of the 66 patients remaining euthyroid in 1973 were available
for study. Hypothyroidism had developed in a further three
patients in whom the plasma TSH levels remained essentially
unchanged (32-8 and 32-0, 23-5 and 26-1, and 27-5 and 31-2
fiU/ml).
TABLE I—Mean Serum T-4 and Plasma TSH Levels (±S.E.) in 69 Patients with
High Plasma TSH Levels in 1972 and in 66 and 61 Patients Remaining
Euthyroid in 1973 and 1974. All were Treated with 1311 for Thyrotoxicosis
between 1954 and 1966
Serum T-4 Plasma TSH
(M-g/100 ml) (nU/ml)
February 1972 6-8+0-1 25-0+2-0
May 1973 6-5 +0-1 22-6 + 1-8
February 1974 6-5+0-1 21-6+2-0
All 61 euthyroid patients with normal plasma TSH levels in
1972 remained euthyroid over a 24-month period and the mean
serum T-4 and plasma TSH levels in 1972 and 1974 are shown
in table II. In three of these 61 patients, however, the plasma
TSH became slightly raised—9-4, 9-7, and 12-6 fiU/ml respec¬
tively.
The mean serum T-4 level in the euthyroid patients with a
high plasma TSH was significantly lower than that in the euthy¬
roid patients with a normal plasma TSH both in 1972 (P <0 001)
and in 1974 (P <0 001).
Discussion
The high incidence of hypothyroidism after 131I treatment of
thyrotoxicosis necessitates the follow-up of large numbers of
patients. In most centres patients are seen frequently
in the first post-therapy year, when the incidence of hypo¬
thyroidism is highest, and at intervals of six to 12 months
thereafter on a lifelong basis or until hypothyroidism develops.
Though a low serum T-4 is a good index of impending hypo¬
thyroidism in the early months after radioiodine treatment
(Toft et al., 1974) it has not proved possible to predict the onset
of hypothyroidism in patients treated in earlier years. A low
serum T-4 does not have the same significance in such
patients as it may persist indefinitely while the euthyroid state
is maintained by high or normal levels of circulating triiodo¬
thyronine (Sterling et al., 1971; Bellabarba et al., 1972). Over
half (58%) of the patients treated with 131I for thyrotoxicosis
between 1954 and 1966 had high plasma TSH levels
in February 1972 when euthyroid. These high levels, con¬
sidered to be a sensitive index of thyroid failure, remained un¬
changed over 24 months in most of the patients but hypo¬
thyroidism occurred at a rate of 5% a year. On the other hand,
no patient in whom a normal plasma TSH level was found in
February 1972, six to 18 years after radioiodine treatment,
developed hypothyroidism over the same 24-month period.
It is suggested that in the long-term follow-up of patients
treated with 131I for thyrotoxicosis those with a high plasma
TSH level should be examined at yearly intervals as they are at
risk of developing hypothyroidism, whereas those with a low
plasma TSH level should be seen at intervals of two years or
longer.
One possible interpretation of the significantly lower mean
serum T-4 levels in the euthyroid patients with high plasma
TSH levels compared with the euthyroid patients with normal
plasma TSH levels after 131I therapy is chat the serum T-4
levels iin the former group were suboptimal. Any increase
in morbidity, such as ischaemic heart disease, in these
patients will become apparent only in future years, and at pre¬
sent no thvroxine renlacement therapy has been instituted.
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ANOMALOUS PLASMA TSH LEVELS IN PATIENTS DEVELOPING
HYPOTHYROIDISM IN THE EARLY MONTHS AFTER 1311 THERAPY
FOR THYROTOXICOSIS
*A.D. TOFT, *+W.J. IRVINE, QW.M. HUNTER, X.T. G. RATCLIFFE
and t J. SETH.
*Department of Endocrinology, Royal Infirmary; University Departments
of +Therapeutics and + Clinical Chemistry; OMRC Radioimmunoassay Team,
Edinburgh and Radioimmunoassay Unit, Stobhill Hospital, Glasgow.
Abstract: Serial measurements of serum T3, T4 and plasma TSH were
made in seven patients developing hypothyroidism in the early months after
131f therapy for thyrotoxicosis. In each patient a low serum T4 was found
in the presence of a normal plasma TSH before the onset of clinical hypo¬
thyroidism. In three of the patients the normal plasma TSH was associated
with normal or high serum T3, but in the other four patients both serum T3
and T4 were low in association with a normal plasma TSH. Such a situation
may reflect the slow response of the brain-thyroid axis recently exposed to
high circulating levels of thyroid hormone, analogous to the suppression of
the brain-adrenal axis after prolonged exposure to high circulating levels of
corticosteroids .
It has recently been reported that
a low serum T4 may be associated
with a normal plasma TSH in patients
developing hypothyroidism in the
early months after treatment
for thyrotoxicosis (1). Although
serum T3 was not measured, it was
suggested that both the euthyroid
state and the suppression of plasma
TSH were temporarily maintained by
normal or high levels of serum T3.
The present paper reports serial
serum T3, T4 and plasma TSH
levels in seven such patients.
Patients and Methods
Seven of thirty-one consecutive
patients developing hypothyroidism
in the early months following ^lj
treatment of thyrotoxicosis were
found to have a low serum T4 (<4. 5
pg/100ml) in association with a nor¬
mal plasma TSH (<7.4pu/ml) when
euthyroid. Each patient had been
examined clinically by one observer
(A. D„ T. ) at 3-8 weekly intervals
after therapy and blood withdrawn
for the estimation of serum T3, T4
and plasma TSH. The diagnosis
of hypothyroidism was made clini¬
cally and on the basis of a low ser¬
um T4 and a high plasma TSH.
Serum T4 was estimated by com¬
petitive protein-binding analysis
(normal range 4.5-11.5 pg/ 100ml)
(2), serum T3 by radioimmunoassay
(normal range 0. 6- 1. 8ng/ml) (3),
and plasma TSH by radioimmuno¬
assay (4).
Results
In three of the patients a low
serum T4 and a normal plasma TSH
were associated with serum T3
levels of 2. 24, 1. 2 and 0. 88ng/ml
1-2 months after therapy with I'll.
Pituitary TSH secretion was pres-
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Figure 1. Serum T4, T3 and plasma TSH levels in the four patients in whom
a low serum T4 and T3 level was observed in the presence of a normal
plasma TSH prior to the development of hypothyroidism.
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umably suppressed albeit temporar¬
ily, by the high or normal serum T3
concentrations, but as the serum T3
fell in subsequent weeks, not necess¬
arily into the hypothyroid range, the
plasma TSH rose and clinical hypo¬
thyroidism developed.
In the remaining four patients a
low serum T3, low serum T4 and a
normal plasma TSH were observed
while the patient was clinically euth¬
yroid (Fig. 1). Again this pheno¬
menon was temporary and in each
case not only was the plasma TSH
elevated one month later, but hypo¬
thyroidism had developed in three
of the four patients. The fourth
patient remained clinically euthyroid
despite low serum T3 and T4 levels
and a high plasma TSH for two
months .
Discussion.
It is well recognised that patients
may be euthyroid many years after
13 If therapy for thyrotoxicosis des¬
pite low serum T4 and high plasma
TSH concentrations. The serum T3
is normal or high in such a group(5).
The thyroid remnant presumably
fails to meet secretory demands,
pituitary TSH output is no longer
suppressed, and the resulting rise
in the level of the plasma TSH incre¬
ases the T3/T4 ratio and the euthy¬
roid state may be maintained indef-
RAPID COMMUNICATIONS 609
initely.
In the present study four patients
developing hypothyroidism in the
early months after treatment
were noted to have the transient phe¬
nomenon of low serum T3 and T4
in the presence of a normal TSH
which became elevated in the subse¬
quent month. It is possible that the
metabolic effects of T3 and T4 at
the hypothalamic and/or thyrotroph
level persist for some time after an
alteration in circulating thyroid hor¬
mone concentration, and the plasma
TSH remains suppressed despite low
levels of serum T3 and T4. Indeed
if T3 replacement therapy is with¬
drawn from athyreotic patients plas¬
ma TSH levels remain suppressed
for some days (6). An alternative
explanation may be suppression of
the brain-thyroid axis by excess
circulating thyroid hormone in thy¬
rotoxic patients; an analogous sit¬
uation occurs in the suppression of
the brain-adrenal axis in patients
exposed to prolonged high levels of
circulating corticosteroids. A
sluggish response of the pituitary
thyrotrophs to the presence of low
serum thyroid hormone levels in
131
patients recently treated with I
for thyrotoxicosis might therefore
be expected.
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THYROID FUNCTION IN THE LONG-TERM
FOLLOW-UP OF PATIENTS TREATED WITH
IODINE-131 FOR THYROTOXICOSIS
A. D. Toft W. J. Irvine
J. Seth W. M. Hunter
E. H. D. Cameron
Department of Endocrinology, Royal Infirmary;
University Departments of Therapeutics and Clinical
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In February, 1972, 58% of patients
ummary eutj1yr0;(j after iodine-131 therapy for
thyrotoxicosis between 1954 and 1966 had a raised
plasma thyroid-stimulating-hormone (t.s.h.) (>7-4
mU/1) and 42% a normal t.s.h. level. A group of 69
of the euthyroid patients with a raised plasma t.s.h.
(25-0±2-0 mU/1) in 1972 was re-examined annually
for three years. There was no apparent change in the
mean plasma t.s.h. level between 1972 and 1975 in the
patients remaining euthyroid, but overt hypothyroid¬
ism developed in 3 patients in 1973, in a further 3
patients in 1974, and in 1 patient in 1975. In contrast,
none of a group of 61 patients, euthyroid with a normal
plasma t.s.h. (4-0 ±0-2 mU/1) in 1972, developed overt
hypothyroidism over the next three years, although
slightly raised t.s.h. levels were recorded in 3 patients
in 1974 and in a further 6 patients in 1975. Both the
mean serum T-4 and T-3 in the euthyroid patients with
a raised plasma t.s.h. were significantly lower, but still
in the respective normal ranges, than those in the
euthyroid patients with a normal plasma t.s.h. No
significant difference in the fasting serum-cholesterol
or triglyceride levels could be demonstrated between
the two groups. Since no patient with a normal
plasma t.s.h. after iodine-131 treatment for thyro¬
toxicosis six to eighteen years earlier developed overt
hypothyroidism over a three-year period, the follow-up
of such patients need not be so frequent as that of
similarly treated euthyroid patients with a raised
plasma t.s.h. in whom overt hypothyroidism develops
at the rate of 2-5% per year.
Introduction
The treatment of thyrotoxicosis with radio-iodine
results in a high incidence of hypothyroidism—
2
greatest in the first post-treatment year at 7-22%, and
continuing at 2-5% per annum thereafter,1 with a
cumulative incidence of 80% fifteen years after therapy
in some centres.2 Thyroid failure developing in the
early months after iodine-131 treatment is not difficult
to diagnose, and a low serum-thyroxine (T-4) is the
most sensitive index of impending hypothyroidism.3
On the other hand, the diagnosis of hypothyroidism
which develops insidiously many years later is more
difficult. Since at least 3000 patients are treated with
radio-iodine for thyrotoxicosis in the United Kingdom
each year, it would be of value to identify those patients
at risk of developing thyroid failure. Although a
raised circulating level of thyrotrophin (thyroid-
stimulating hormone, t.s.h.) is generally a good index
of impaired thyroid function, it is not uncommonly
observed after radio-iodine treatment and may persist
for many months in patients euthyroid by all other
criteria.4-7 It is, therefore, of no value in predicting
when hypothyroidism will develop. However, Toft
et al.5-7 studied patients with normal t.s.h. levels over
a period of two years who had been treated with radio-
iodine for thyrotoxicosis between 1954 and 1966 and
similarly treated patients with raised t.s.h. levels, and
found that all the patients who developed overt hypo¬
thyroidism over the two-year period were derived from
the high-t.s.h. group. Such a finding raises the possi¬
bility of predicting patients in whom hypothyroidism
may develop as a late complication of radio-iodine
therapy by estimating the plasma t.s.h., and thereby
reducing the long-term follow-up commitment of
endocrine units.
The present report is an extension to three years of
the study of these patients treated with iodine-131.
On the basis of the plasma t.s.h. level a more rational
follow-up policy is suggested for the ever-increasing
number of patients who have been treated with radio-
iodine for thyrotoxicosis. Furthermore, by estimating
the circulating triiodothyronine (T-3) and T-4 levels
in addition to plasma t.s.h., it becomes necessary to
re-evaluate the effect of altered function of the brain/
thyroid axis in patients treated with radio-iodine for
thyrotoxicosis.
Patients and Methods
In February, 1972, the serum T-4 and plasma t.s.h.
were estimated in 233 euthyroid patients who had been
treated with iodine-131 for thyrotoxicosis in the endocrine
clinic of the Royal Infirmary, Edinburgh, between 1954
TABLEI—MEANSERUM-4,3ANDT.S.H.L VELS(±S .)IPATI NTW THHIGSERUM.L1972S REMAININGEUTHYROIDANDVAILABLEFORS U YOVERT EFOL OW NGRYE S( RE TEDW THIODIN -131HYROT XI¬ COSISBETWEEN1954AND66) YearNo.f patientsSerumT-4 (nmol/1)SerumT-3 (nmol/1)Plasmat. .h. (mU/1)
No.developingovert hypothyroidism
No.lostt follow-up
1972
69
88*0±1*0
—
25*0±2
—
—
1973
66
84-0±1*
—
22-6d=1-8
3
0
1974
61
84-0±1
—
21-6±2*0
3
2
1975
57
75-0±3-
1*52±0*05
26-6±2
1
3
TABLEII—MEANSERUM-4,3AND.S.H.(±S .)P TI NTSW THNORMALPLAS AT. . .LEV L1972 REMAININGWITHNORMALPL SMAT.S. .LEVELSANDAVAILABLEFORSTU YOHEF LLOWINGTHREEY AR( RE T D IODINE-131FORTHYROTOXICOSISBETWEEN1954A D66) YearNo.f patientsSerumT-4 (nmol/1)SerumT-3 (nmol/1)Plasmat. .h. (mU/1)No.developingovert hypothyroidism
No.developingraised plasmat.s.h.
No.lostt follow-up
1972
61
113*0±4*
—
40±0*2
—
—
—
1974
58
105*0±3*0
—
4*1±0*3
0
3
0
1975
47
105*0±4*
1*73±005
3-9±0*3
0
6
5
4
and 1966. A group of 69 of these euthyroid patients with a
raised plasma t.s.h. was studied again each year for three
years, and a further group of 61 euthyroid patients with a
normal plasma t.s.h. was studied again at two and at three
years. The mean age of each group in 1975 was 63 years.
The number of patients chosen for this follow-up study
was arbitrarily determined as adequate for the purpose of
the present study. Each patient was examined clinically
by one observer (A. D. T.) and blood was withdrawn for
the estimation of serum T-4, T-3 (1975 only), and plasma
t.s.h. In addition, in 1975, the patients fasted overnight
for thirteen hours prior to venepuncture, for the estimation
of serum cholesterol and triglycerides. Hypothyroidism
was diagnosed on clinical grounds and on the basis of a
low serum T-4 (<58 nmol/1) and a raised plasma t.s.h.
(>7-4 mU/1). For the present purpose the euthyroid
state is defined as being when the patient is euthyroid
clinically and when the serum T-4 level is within the normal
range, irrespective of the level of plasma t.s.h.
Serum T-4 was measured by competitive protein-bind¬
ing analysis 8 in 1972-74 and by radioimmunoassay 9 in
1975. Values obtained by these two methods showed no
statistically significant difference. Serum T-3 was only
measured in 1975, by radioimmunoassay under conditions
essentially identical to those described for T-4. The sensi¬
tivity of the T-3 assay was 0-25 nmol/1, and interassay
precision in the euthyroid range was 9 0% as coefficient of
variation. Plasma t.s.h. was estimated, as previously des¬
cribed.10 Serum cholesterol and triglycerides were mea¬
sured by ' AutoAnalyzer' (Technicon Instruments Co:)
methods.11'12
Results
In February, 1972, the plasma t.s.h. was raised in
136 (58%) of the 233 patients euthyroid after iodine-
131 therapy and normal in 97 (42%).
The mean (±s.e.) serum T-4, T-3, and plasma
t.s.h. levels in the 69 euthyroid patients with a high
plasma t.s.h. in 1972 and in those remaining euthyroid
and available for study in 1973, 1974, and 1975 are
shown in table i. Only 3 of these 69 patients developed
overt hypothyroidism in the first year of follow-up;
the plasma t.s.h. had risen in 1 (from 34-6 to 67-3 mU/1),
had fallen in the 2nd (from 45-6 to 28-2 mU/1), and
had remained virtually unchanged in the 3rd (90-4 and
92-8 mU/1). At two years 64 of the 66 remaining
euthyroid in 1973 were available for study, and overt
hypothyroidism had developed in a further 3 patients
in whom the plasma t.s.h. remained essentially
unchanged (32-8 and 32 0, 23-5 and 26-1, 27-5 and
31-2 mU/1). At three years, 58 of the 61 patients
remaining euthyroid in 1974 were available for study,
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and overt hypothyroidism had developed in 1 further
patient in whom the plasma t.s.h. level rose from 39-0
to 64-0 mU/1. The mean (±s.E.) serum T-4, T-3, and
t.s.h. levels in the 61 patients with a normal plasma
t.s.h. in 1972 and in those remaining with a normal
plasma t.s.h. and available for study in 1974 and 1975
are shown in table ii. None of the 61 euthyroid
patients with a normal plasma t.s.h. in 1972 developed
hypothyroidism over the period 1972-75. Between
1972 and 1974 plasma t.s.h. became slightly raised in
3 patients (9-4, 9-7, and 12-6 mU/1), and between 1974
and 1975 it became elevated in a further 6 patients
(81, 8-3, 9-2, 10-7, 12-8, and 13-2 mU/1). 5 patients
were lost to follow-up.
The mean serum T-4 in the euthyroid patients
with a raised plasma t.s.h. was significantly lower than
that in the euthyroid patients with a normal plasma
t.s.h. in 1972, 1974, and 1975 (p<0001 on each
occasion). In addition, the mean serum T-3 was
significantly lower in the euthyroid patients with a
raised plasma t.s.h. than in the euthyroid patients
with a normal plasma t.s.h. (p<0001). Mean serum
T-3 and T-4 levels in the patients with normal t.s.h.
levels did not differ significantly from the mean values
observed for a normal population (1-70 and 107
nmol/1, respectively).
The mean (±s.e.) serum cholesterol and triglyceride
levels in 40 euthyroid patients (33 female, 7 male)
with normal t.s.h. levels and in 40 euthyroid patients
with high t.s.h. levels matched for age and sex are
shown in table ill. There was no significant difference
either in mean serum cholesterol or triglyceride con¬
centrations or in their distribution frequencies
between the two groups.
Discussion
The present study has confirmed that, in the
majority of euthyroid patients with a raised plasma
table hi—mean serum cholesterol and triglyceride levels
(±s.e.) in 40 euthyroid patients with normal plasma
t.s.h. levels and in 40 euthyroid patients with high
plasma t.s.h. matched for age and sex (all treated with
iodine-131 for thyrotoxicosis between 1954 and 1966)
t.s.h. level Serum-cholesterol
(nmol/1)
Serum-triglyceride
(nmol/1)
Normal
High
6-36 ±017
6-53±019
1-24 ±007
1-41 ±0-12
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t.s.h. following iodine-131 treatment of thyrotoxicosis,
the t.s.h. level will remain unchanged for long periods,
although hypothyroidism will continue to develop in a
small proportion. On the other hand, in no patient
with a normal plasma t.s.h. six to eighteen years after
radio-iodine therapy did hypothyroidism develop over
a three-year period of review, although the plasma
t.s.h. became elevated in 5% of these patients each
year. These findings are highly relevant to the
organisation of the long-term follow-up of radio-
iodine-treated thyrotoxic patients. In our clinic, 20%
of patients who remain euthyroid one year after radio-
iodine therapy for thyrotoxicosis have a raised plasma
t.s.h., and from the present study this figure increases
to 58% at a mean twelve years after treatment. If an
annual rate of hypothyroidism of 2% is assumed
between one and twelve years after therapy, the calcu¬
lated annual rate of transfer of patients from a normal
to a high plasma t.s.h. is 5-5%, which is very similar to
that of 5% per year observed between 1972 and 1975
in the euthyroid patients with normal plasma t.s.h.
levels after radio-iodine treatment six to eighteen years
earlier. It would appear, therefore, that plasma t.s.h.
levels are of the same significance in patients from one
to eighteen years after radio-iodine therapy. Plasma
t.s.h. should be estimated at one year after treatment,
when the early high incidence of hypothyroidism is
over, and patients grouped into (1) those with a high
plasma t.s.h. who tequire annual review and (2) those
with a normal plasma t.s.h. who require to be reviewed
at most every three years. Such a policy would reduce
considerably the follow-up of the ever-increasing
numbers of patients who have been treated with
iodine-131 and who have all been reviewed at least
on an annual basis in the past either in an endocrine
clinic or by means of a computerised follow-up
programme.
It is important to consider whether a raised plasma
t.s.h. following radio-iodine is simply an indication for
annual review of the patients known to be at risk of
developing hypothyroidism in future years, or whether
it is a sign of existing thyroid failure albeit subclinical.
Previous studies of t.s.h. levels after treatment of
thyrotoxicosis by iodine-131 or partial thyroidectomy
have shown serum T-4 levels to be significantly lower
in patients with a raised plasma t.s.h. than in tnose
with a normal plasma t.s.h. 6'7'13 No difference,
however, was observed in the serum T-3 between the
two groups.6-13 The maintenance of clinical euthyroid-
ism by T-3 in patients with a high plasma t.s.h. level
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was considered to reflect a compensatory mechanism
which is probably t.s.h.-dependent. In contrast, the
present study has shown, not only serum T-4, but also
serum T-3 levels in patients with a high plasma t.s.h.
to be significantly lower than the thyroid-hormone
levels of the patients with a normal plasma t.s.h. after
radio-iodine treatment. The falling T-3 and T-4
secreted by the irradiated thyroid gland will result in a
raised plasma t.s.h. but, unlike the situation in iodine-
deficiency goitre, for example, the irradiated thyroid
may be unable to respond to a high circulating t.s.h.
level with a compensatory increase in thyroid-hormone
secretion. According to the dose of irradiation, which
will vary from follicle to follicle, there may occur delay
in mitosis followed by normal mitosis, delayed mitosis
followed by cell death in mitosis, inhibition of mitosis
or cell sterilisation, reduced cell life-span, and cell
death.14 It is possible that the irradiated thyroid cell,
unlike the normal cells, is unable to hypertrophy in
response to t.s.h. or thyroid-stimulating antibodies,
and thyroid stimulators, by inducing mitosis, may
paradoxically increase the rate of cell death within
the gland. Raised plasma t.s.h. may, therefore, simply
reflect the reduced output of both T-3 and T-4 by the
failing thyroid gland which is incapable of compen¬
satory increase in thyroid-hormone secretion as a
result of irradiation damage.
It is not possible at present to determine whether
the suboptimal serum T-3 and T-4 levels in these
patients with elevated plasma t.s.h. after iodine-131
treatment indicate existing significant hypothyroidism.
It is well established that the pituitary thyrotroph is
very sensitive to minor changes in the serum levels
of T-3 and T-4,15 but other organs and tissue may be
less sensitive to changes in circulating thyroid-hormone
levels. Indeed, no difference could be demonstrated in
serum cholesterol or triglyceride levels between the
high and normal t.s.h. patients matched for age and
sex, although hypercholesterolemia is well recognised
in overt hypothyroidism.16-19 It is clear that any
increase in morbidity or mortality in the patients with
raised t.s.h. levels and suboptimal T-3 and T-4
concentrations in the serum will only become apparent
on long-term follow-up, and such a study is in progress.
If the patients with suboptimal thyroid-hormone
levels and a raised plasma t.s.h. are considered to be
hypothyroid, it is important to recognise the possi¬
bility of inducing thyrotoxicosis in some of the patients
if the usual thyroxine replacement dosage of 0-1 to 0-2
mg is employed. The thyroid remnant may be autono-
8
mous due to circulating thyroid-stimulating anti¬
bodies, and evidence for autonomous function is
provided by the observation that the iodine uptake of
the gland is uninfluenced by pharmacological doses of
exogenous t.s.h. despite normal levels of endogenous
plasma t.s.h. in some patients previously treated with
radio-iodine.10 If clinically euthyroid patients with
suboptimal T-3 and T-4 levels and raised plasma
t.s.h. are to be treated with thyroxine, it would be
ideal if the replacement therapy could be adjusted
such that the levels of plasma t.s.h. in response to
intravenous thyrotrophin-releasing hormone lie within
the normal range.
We are grateful to Dr M. F. Oliver and Miss Margaret Millar
for the serum cholesterol and triglyceride estimations and to
Prof. Roger Ekins for the gift of T-3 antiserum.
Requests for reprints should be addressed to W. J. I., Depart¬
ment of Therapeutics, Royal Infirmary. Edinburgh EH3 9YW.
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PARTIAL FAILURE OF ANTERIOR PITUITARY AND
THYROID PRESENTING AS MYXOEDEMA
By
A. D. Toft and W. J. Irvine
ABSTRACT
The development of a sensitive radioimmunoassay of plasma thyrotrophin
(TSH) and the isolation and synthesis of thyrotrophin-releasing hormone
(TRH) allows a precise evaluation of the disordered brain-thyroid axis.
The present report describes a patient who presented with myxoedema
due to partial failure of both the anterior pituitary and the thyroid gland.
The degree of impaired function of either gland alone would not have
caused her clinical presentation.
CASE REPORT
A 58 year old female school teacher presented in July 1973 to the Endocrine
Clinic of the Royal Infirmary, Edinburgh, with the features of myxoedema.
There was no goitre. The total serum thyroxine (serum T4) measured by com¬
petitive protein binding (Seth 1973) was 1.0 /j.g/100 ml (normal 4.5-11.5 ^g/100
ml), plasma TSH measured by radioimmunoassay (Irvine et al. 1973) 30 /rU/rnl
(normal <7.4 /rU/ml) and antibodies were detected to thyroglobulin in a titre
of 1:2500 by the tanned cell haemagglutination method. Antibodies against
thyroid cytoplasm were negative by the complement fixation and the indirect
immunofluorescence tests. The 4 h ,32I uptake by the thyroid gland increased
normally from 13-26% in response to bovine TSH ("Thytropar") 10 IU im
daily for three successive days (Irvine et al. 1973), suggesting a diagnosis of
pituitary hypothyroidism. Tomography of the pituitary fossa was normal and
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the visual fields were intact on formal testing. Urinary luteinising hormone
(LH) measured by haemagglutination inhibition was low for a post-menopausal
female at 23.3 IU/24 h (normal > 36 IU/24 h). A standard insulin tolerance
test was performed using 0.1 units soluble insulin/kg - body weight. The blood
glucose (glucose oxidase method) fell to 8 mg/100 ml, but the plasma growth
hormone (GH) level measured by radioimmunoassay (HGH-125 Imusay, Abbott
Laboratories) was undetectable throughout the test. The plasma 11-hydroxy-
corticosteroids (11-OHCS) (Mattingly 1962) and the plasma prolactin measured
by radioimmunoassay (Cole 8c Boyns 1973) increased normally from 21 to
45 /(g/100 ml and from 0.19 to 0.59 mU/'ml respectively. The elevated basal
plasma TSH level of 30 /iU/ml was unchanged at 20 and 60 min after the
rapid iv injection of 200 /,ig TRH.
When the patient had been taking L-thyroxine 0.15 mg daily for five months
the brain-thyroid axis was re-investigated. She was clinically euthyroid, with
a serum T4 of 8.0 /(g/100 ml and a plasma TSH of < 1.2 /tU/ml which re¬
mained undetectable following 200 jug TRH iv. Urinary LH remained low at
26.2 IU/24 h. Plasma GH increased on this occasion to 8.0 ng/ml during in¬
sulin-induced hypoglycaemia, the blood glucose falling to 10 mg/100 ml. Plasma
11-OHCS and prolactin levels rose normally during the test. The patient has
been followed up for 18 months and remains well. There is no clinical or
radiological evidence of pituitary tumour.
COMMENT
We have not observed a patient with a primary hypothyroidism in whom the
absolute increase in the 4 h 132I uptake by the thyroid gland was more than
8fl/o following exogenous bovine TSH (Irvine et al. 1973). Unless an intra-
thyroidal enzyme defect was present, which is unlikely in the absence of either
a goitre or a high radioiodine uptake, the demonstration of a raised plasma
TSH, a high titre of circulating thyroid antibodies but a normal TSH stimula¬
tion test indicates an impaired thyroid reserve which in the presence of a
normal anterior pituitary gland would not be associated with clinical evidence
of hypothyroidism. The low urinary gonadotrophins before and after thyroxine
replacement therapy suggest an element of pituitary failure. A lack of growth
hormone response to insulin hypoglycaemia is well described in primary hypo¬
thyroidism (lwatsubo et al. 1967), but the response in our patient was blunted
after five months of adequate thyroxine replacement therapy. Furthermore the
elevated plasma TSH level of 30 /tU/ml did not rise following TRH, implying
that the thyrotrophs were already secreting TSH to their maximum capacity.
In the presence of a normal thyroid gland such a degree of anterior pituitary
failure would not cause myxoedema, but in the present case the elevated plasma
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TSH was insufficient to maintain a failing thyroid gland and the combination
of partial anterior pituitary and partial thyroid failure led to the development
of clinical hypothyroidism. We believe this to be the first such case described
but with the widespread clinical use of TRH and the radioimmunoassay of
TSH more examples may be reported. Although it is tempting to postulate an
autoimmune basis for both the thyroid and anterior pituitary dysfunction, cir¬
culating antibodies to anterior pituitary tissue were not detected by indirect
immunofluorescence.
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SHORT COMMUNICATION
ASSESSMENT BY CONTINUOUS CARDIAC
MONITORING OF MINIMUM DURATION OF
PREOPERATIVE PROPRANOLOL TREATMENT
IN THYROTOXIC PATIENTS
A. D. TOFT, W. J. IRVINE and R. W. F. CAMPBELL
Departments of Endocrinology and Cardiology, Royal Infirmary, and
University Department of Therapeutics, Edinburgh
(Acceptedfor publication 4 December 1975)
SUMMARY
The effect of the beta-blocker, propranolol (40 mg 6-hourly orally) has been
studied on the tachycardia of six patients with untreated thyrotoxicosis. Heart rate
was monitored continuously using a light portable ECG recorder which allowed
the patients to undertake normal activities during the recording periods. The most
marked reduction in heart rate was evident at 24 h after starting propranolol
treatment. In three of the patients there was only a minor further fall in heart
rate despite continued propranolol administration, but in the remaining patients
the reduction in heart rate with each successive day of treatment was more marked.
These results suggest that if propranolol were to be used alone in the preparation of
patients before partial thyroidectomy for thyrotoxicosis, a dose of 40 mg 6-hourly
for 3-4 days might be sufficient.
The beta-adrenergic blocking drug, propranolol, is effective in relieving many of the periph¬
eral manifestations of thyrotoxicosis (Shanks et ah, 1969). It has been used successfully
in the treatment of thyrotoxic crisis (Das & Kreiger, 1969), and is a useful adjunct to iodine-
131 in the treatment of thyrotoxicosis, controlling symptoms until the radioactive iodine
has a therapeutic effect (Hadden et al., 1968). It has the considerable added advantage in the
post-irradiation period of not causing any change in the levels of circulating thyroid
hormone and therefore allowing the response to therapy to be more readily assessed. How¬
ever, propranolol is considered to be inferior to carbimazole as a long-term treatment of
thyrotoxicosis (McLarty et al., 1973), and the metabolic consequences of prolonged adren¬
ergic blockade in thyrotoxicosis, such as osteoporosis, have not yet been fully elucidated.
Recently, Lee et al. (1973) and Michie et al. (1974) have reported their experience with pro¬
pranolol as the sole preoperative agent in patients undergoing partial thyroidectomy for
thyrotoxicosis. Such a regime would appear to have certain advantages over the conven¬
tional form of pre-operative preparation with carbimazole and iodine and it is therefore
Correspondence: Dr W. J. Irvine, Department of Endocrinology, Royal Infirmary of Edinburgh, Edin¬
burgh EH3 9YW.
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important to establish the rate of effect of propranolol in rendering a patient with thyro¬
toxicosis suitable for surgery. The present paper assesses the response of heart rate to pro¬
pranolol by continuous ECG monitoring of patients with thyrotoxicosis in an attempt to
define the minimum pre-operative period of treatment.
Patients and methods
Six patients were studied (four females, two males) aged 26-63 years. The diagnosis of
thyrotoxicosis was made on clinical grounds and on the basis of the effective thyroxine ratio
(Toft et al., 1973), the total serum thyroxine measured by radioimmunoassay (Seth et al.,
1975), and the 4 h uptake of iodine-132 by the thyroid gland. In addition, there was no rise
in the plasma TSH level, following the intravenous injection of 200 /tg thyrotrophin releas¬
ing hormone. One patient was studied as an out-patient and five as in-patients. The in¬
patients were allowed at least 24 h to acclimatize to the hospital environment before starting
continuous monitoring. The heart rate monitoring was carried out with miniature tape
recording equipment (Oxford Instruments) using a modified V.5 chest electrode. The light
weight and portability of these instruments allowed the patients to undertake normal
activity during the recording periods. The C. 120 'Memorex' tape cassettes were turned
over at the end of 24 h and the batteries and tape cassettes were changed every 48 h. Care
100
A
0 2 3 4
Days on propranolol
Fig. 1. The effect of oral propranolol 40 mg 6-hourly on the continuously monitored heart rate
of six patients with untreated thyrotoxicosis.
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was taken to ensure that tape recorder speed variations were minimized by using the same
recorder for each patient over the taping period. The first day of monitoring was the control
day and thereafter propranolol was administered orally in a dose of 40 mg 6-hourly and
monitoring continued for a further 3-4 days. The completed tapes were replayed at 60 times
real-speed and were checked by two independent observers. The signal was also processed
by a Neilson Arrythmia Computer (Neilson, 1974), which provided continuous heart rate
measurements. These rates were stored in a solid state memory device with 240 individual
stores. Each store therefore contained heart rate information for a 6 min period of the 24 h
tape recording. In the final analysis the number of 6 min periods during which more than
600 sinus beats had been detected was expressed as a percentage of the total number of 6 min
periods. This was effectively the proportion of time during which the heart rate was over
100 beats per minute.
Results
The effect of oral propranolol in a dose of 40 mg every 6 h for 3-4 days on the continu¬
ously recorded heart rate of six patients with untreated thyrotoxicosis is shown in Fig. 1.
The greatest reduction in heart rate occurred during the first day of treatment with pro¬
pranolol in the five patients in whom data was available for this period. In the sixth patient
there was a failure of the recording system on the first day of therapy. In three of the patients
there was only a small further fall in heart rate despite continued propranolol administra¬
tion, but in the remaining patients there was a more apparent reduction in heart rate with
each successive day of treatment. The effect of propranolol was not related to the severity
of the thyrotoxicosis. The out-patient showed as good a response as the in-patients.
Discussion
Although the time course of action of intravenous propranolol on the heart rate, cardiac
output and tremor of patients with thyrotoxicosis has been well documented (Howitt &
Rowlands, 1966; Marsden et al., 1968) the rate of response of these variables following
oral therapy has not been fully evaluated. Vinik et al. (1968) demonstrated a significant fall
in pulse rate in thyrotoxic patients 48 h after starting treatment with oral propranolol, but
we are unaware of any more detailed studies.
In view of the demonstration that partial thyroidectomy may be safely performed in
thyrotoxic patients prepared solely with propranolol (Lee et al., 1973; Michie et al., 1974),
it is important that the minimum time of preparation of patients for surgery is established
if such a form of therapy is to become more widely practised. A disadvantage of carbi-
mazole therapy for thyrotoxicosis is the relapse rate of more than 50% after 18 months of
treatment. The treatment of thyrotoxicosis primarily by partial thyroidectomy after prepara¬
tion with propranolol is therefore an attractive proposition. The present study suggests that
the pre-operative period of preparation with propranolol 40 mg 6-hourly orally could be
3-4 days.
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